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Abstract 
The primary aim of this study was to investigate the feasibility of the amphiphilic block 
copolymer poly((vinylpyrrolidone)-b-poly(vinyl acetate)) (PVP-b-PVAc) as a vehicle for 
hydrophobic anti-cancer drugs. 
 
PVP-b-PVAc block copolymers of constant hydrophilic PVP block length and varying 
hydrophobic PVAc block lengths were synthesized via xanthate-mediated controlled radical 
polymerization (CRP). The methodology consisted of growing the PVAc chain from a xanthate 
end-functional PVP. In an aqueous environment the amphiphilic block copolymers self-
assembled into spherical vesicle-like structures consisting of a hydrophobic PVAc bilayer 
membrane, a hydrophilic PVP corona and an aqueous core. The self-assembly behaviour and the 
physicochemical properties of the self-assembled structures were investigated by 1H NMR 
spectroscopy, fluorescence spectroscopy, transmission electron microscopy (TEM) and dynamic 
and static light scattering. 
 
Drug loading studies were performed using a model hydrophobic drug, clofazimine, and a 
common anti-cancer drug paclitaxel (PTX) to evaluate the potential of the PVP-b-PVAc block 
copolymers for drug delivery,. Clofazimine and PTX were physically entrapped into the 
hydrophobic domain of the self-assembled PVP-b-PVAc block copolymers via the dialysis 
method. The drug-loaded PVP-b-PVAc block copolymers were characterized regarding particle 
size, morphology, stability and drug loading capacity in order to assess their feasibility as a drug 
vehicle. The polymer vesicles had a relatively high drug loading capacity of 20 wt %. The effect 
of the hydrophobic PVAc block length on the drug loading capacity and encapsulation efficiency 
were also studied. Drug loading increased with increasing the hydrophobic PVAc block length. 
The effect of the drug feed ratio of clofazimine and PTX on the drug loading capacity and 
encapsulation efficiency were also investigated. The optimal formulation for the drug-loaded 
PVP-b-PVAc was determined and further investigated in vitro. The size stability of the drug-
loaded PVP-b-PVAc block copolymers was also assessed under physiological conditions (PBS, 
pH 7.4, 37 °C) and were stable in the absence and presence of serum. 
 
 
Stellenbosch University http://scholar.sun.ac.za
PVP-b-PVAc block copolymers were tested in vitro on MDA-MB-231 multi-drug-resistant 
human breast epithelial cancer cells and normal MCF12A breast epithelial cells to provide 
evidence of their antitumor efficacy. In vitro cell culture studies revealed that the PVP-b-PVAc 
drug carrier exhibited no cytotoxicity towards MDA-MB-231 and MCF12A cells, confirming the 
biocompatibility of the PVP-b-PVAc carrier. In vitro cytotoxicity assays using clofazimine-PVP-
b-PVAc formulations showed that when MDA-MB-231 cells were exposed to the formulations, 
an enhanced therapeutic effect was observed compared to the free drug. Cellular internalization 
of the PVP-b-PVAc drug carrier was demonstrated by fluorescent labeling of the PVP-b-PVAc 
carrier. Fluorescence microscopy results showed that the carrier was internalized by the MDA-
MB-231 cells after 3 hours and localized in the cytoplasm and the perinuclear region. 
 
Overall, it was demonstrated that PVP-b-PVAc block copolymers appear to be promising 
candidates for the delivery of hydrophobic anti-cancer drugs. 
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Opsomming 
Die studie is gebaseer op die gebruik van amfifieliese blokkopolimere van poli((N-
vinielpirolidoon)-b-poli(vinielasetaat)) (PVP-b-PVAc) as potensiële geneesmiddeldraers. 
 
PVP-b-PVAc blokkopolimere van konstante hydrofiliese bloklengte en verskillende 
hydrofobiese bloklengte is voorberei via die RAFT/MADIX-proses. Blokkopolimere met 
vinielasetaat is vanaf poli(N-vinielpirolidoon) met ‘n xantaatendfunksie voorberei. In ‘n 
wateromgewing vorm die PVP-b-PVAc blokkopolimere vesikel strukture met ‘n 
hydrofobiese membraan en ‘n hydrofiliese mantel. 
 
Die fisies-chemiese eienskappe van die PVP-b-PVAc blokkopolimere is gekarakteriseerd 
met gebruik van KMR spektroskopie, fluoresent spektroskopie, transmissie 
elektronmikroskopie (TEM) en dinamiese en statiese lig verstrooiing. 
 
Die potensiaal van PVP-b-PVAc as ‘n geneesmiddeldraer is ondersoek deur gebruik te 
maak van die hydrofobiese geneesmiddel, clofazimine, en ‘n anti-kanker geneesmiddel, 
paclitaxel. Clofazimine en paclitaxel is ge-inkapsuleer in die hydrofobiese gedeelte van 
die blokkopolimere via die dialise-metode. Clofazimine-PVP-b-PVAc en paclitaxel-PVP-
b-PVAc blokkopolimere is gekarakteriseerd met betrekking tot die partikel grootte, 
morfologie, stabiliteit en laai kapasitiet om die PVP-b-PVAc blokkopolimere as 
geneesmiddeldraers te evalueer. Die PVP-b-PVAc geneesmiddeldraer het ‘n relatiewe 
hoë laai kapsiteit van 20 gew % aangetoon. Die invloed van die bloklengte op die laai 
kapasitiet is ook ondersoek en beskryf. ‘n Toename in die laai kapasitiet is gesien met ‘n 
toename in die hydrofobiese bloklengte. Die invloed van die hoeveelheid geneesmiddel 
op die laai kapasitiet en die inkapsuleer doeltreffendheid is ook ondersoek. Die optimale 
formulasie is gevind en verder gebruik vir in vitro studies. Die stabiliteit van die 
geneesmiddeldraer in fisiologiese omstandighede (pH 7.4, 37 °C) is ook beskryf. 
Resultate toon aan dat die sisteem stabiel is onder hierdie omstandighede in die 
afwesigheid en aanwesigheid van serum. 
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In vitro eksperimente is op MCF12A epiteel-borsselle en MDA-MB-231 epiteel-
borskankerselle getoets om die anti-tumoraktiwiteit te ondersoek. Resultate toon aan dat 
die PVP-b-PVAc geen sitotoxiese effek op die selle het nie, wat aandui dat die polimere 
bioverenigbaar is. Verder is dit bewys dat die PVP-b-PVAc geneesmiddel formualsie ’n 
hoër sitotoxisiteit besit as die vry-geneesmiddel. Fluoresent studies het aangetoon dat die 
geneesmiddeldraer na 3 uur opgeneen word deur MDA-MB231 selle en gelokaliseerd is 
in die sitoplasma en in die omgewing van die kern van die selle. 
 
In die algemeen is dit aangetoon dat PVP-b-PVAc blokkopolimere potensiële kandidate 
vir die lewering van hydrofobiese geneesmiddels is. 
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To overcome this hurdle, various polymers such as polymer-drug conjugates,7,8 liposomes,9 
polymer micelles10,11 and polymer vesicles,12,13 have been developed as carriers to administer 
hydrophobic drugs. The above mentioned polymer systems are not solely used as solubilizing 
agents for these hydrophobic pharmaceutical agents. Other existing challenges include the 
stabilization and ability for controlled and sustained delivery of these pharmaceutical agents to 
the desired biological sites, which will further improve the therapeutic efficacy of these active 
pharmaceutical agents.14 A drug delivery system can therefore be defined as “one in which a 
drug (one component of the system) is integrated with another chemical, or a drug 
administration device, or a drug administration process to control the rate of drug release, the 
tissue site of drug release, or both.15”  
 
2. Amphiphilic block copolymers for drug delivery 
Amphiphilic block copolymers are composed of a hydrophilic segment and a hydrophobic 
segment. When the polymer is dissolved in selective solvents above their so-called critical 
micelle concentration (CMC), they self-assemble into well-defined structures as illustrated in 
Scheme 1. Depending on the molecular characteristics and molecular weight of the constituting 
blocks, amphiphilic block copolymers can self-assemble into various ordered structures such as 
spherical, worm-like or rod-like micelles, lamellar structures or vesicles.16 The hydrophobic or 
electrostatic interaction is the driving force behind the segregation of the core from the 
surrounding media resulting in core-shell structures.  
 
Polymer micelles are composed of an outer hydrophilic shell and an inner hydrophobic core. The 
hydrophilic shell shields the hydrophobic core and protects it from interactions with blood 
components. This further allows for prolonged circulation times after intravenous administration, 
which is a prerequisite for a drug delivery system. The hydrophobic core acts as a reservoir to 
accommodate bioactive guest molecules such as hydrophobic drugs, which can either be 
physically encapsulated or covalently bound to the core.17,18 On the other hand, polymer vesicles 
(or polymersomes), are usually hollow spheres with a hydrophobic bilayer membrane and 
hydrophilic internal and external coronas (Scheme 1). The hydrated hydrophilic coronas are 
expressed on both the inside and outside of the hydrophobic membrane. 
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Therefore, vesicles have a hydrophilic core, which can accommodate hydrophilic guest 
molecules and a hydrophobic bilayer membrane which can be used to solubilize and retain 
hydrophobic guest molecules. Both the properties of the hydrophilic segment and the 
hydrophobic segment influence the size, stability and the performance of a vesicle as drug 
carrier.  
The attractive properties of amphiphilic block polymers have found great interest and promise in 
the delivery of anticancer agents, anti-inflammatory, antiviral, antibacterial and imaging agents.19 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1: Amphiphilic block copolymers self-assemble into core-shell or vesicular structures in aqueous 
environment. For spherical micelles the hydrophilic shell stabilizes the micelle and protects the 
hydrophobic core which acts a as a depot for hydrophobic guest molecules (top).Vesicle structures have a 
bilayer membrane and hydrophilic core. The hydrophilic core acts as a depot for hydrophilic drugs and 
the hydrophobic bilayer membrane, for hydrophobic drugs (enlarged region)4 
 
The dissertation focuses on the development of an amphiphilic block copolymer comprised of a 
hydrophilic poly(N-vinylpyrrolidone) (PVP) segment and a hydrophobic poly(vinyl acetate) 
(PVAc) segment. PVP is highly hydrophilic, flexible, non-toxic and biocompatible making it an 
attractive candidate for application in drug delivery. PVP has previously found application in 
polymer-drug conjugates and polymeric micelles for the solubilization of hydrophobic drugs,20  
 
20 – 200 nm 
Amphiphilic block copolymer 
Hydrophobic drug 
> 200 nm 
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hydrogels,21 tissue engineering22,23 and in pharmaceutical formulations.24 Interestingly, its 
application as a shell-forming block in polymeric micelles has shown superior properties to 
poly(ethylene glycol) (PEG), the most commonly used hydrophilic polymer in drug delivery 
systems.25 PVAc is a hydrophobic polymer used in applications ranging from adhesives, paints, 
additives to pharmaceuticals. PVAc has found use within pharmaceutics as a precursor to 
poly(vinyl alcohol) (PVA), a water-soluble, non-toxic polymer with bio-adhesive properties. 
Block copolymers of PVP-b-PVAc have been previously reported in the literature.26,27,28 To our 
knowledge no publications have been documented on the application and ability of PVP-b-PVAc 
block copolymers as carriers for hydrophobic anti-cancer drugs. 
 
3. Objective of dissertation 
The purpose of the study was to investigate the potential of PVP-b-PVAc block copolymers as a 
drug delivery vehicle for hydrophobic anti-cancer drugs.  
The objectives of the study can be summarized as follows: 
1. To synthesize amphiphilic block copolymers of PVP-b-PVAc via controlled radical 
polymerization (CRP).  
2. To study the self-assembly behaviour of the PVP-b-PVAc block copolymers in aqueous 
media. 
3. To establish the system as a suitable drug carrier by investigating the physiochemical and 
biological properties of the amphiphilic block copolymers. 
4. To demonstrate the potential of PVP-b-PVAc block copolymers as carriers for 
hydrophobic drugs by the physical encapsulation of clofazimine (model drug) and a 
widely used anti-cancer drug, paclitaxel, into the PVP-b-PVAc aggregates. 
5. To conduct in vitro cytotoxicity and cellular uptake studies of the drug-loaded polymer 
carrier in breast cancer cells to provide evidence of their antitumor efficacy. 
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4. Outline of dissertation 
The dissertation comprises six chapters. 
Chapter 1 Introduction and objectives 
A brief introduction to the application of amphiphilic block copolymers in drug delivery is 
described. The objectives of the research project are presented. 
Chapter 2 Historical and theory 
A literature review that provides a comprehensive overview of the critical features of polymer 
drug carriers, including stability, drug loading, drug internalization and drug release of the 
incorporated hydrophobic drugs is presented. 
Chapter 3 Synthesis, characterization and self-assembly of poly(vinylpyrrolidone)-b-
poly(vinyl acetate) 
The chapter addresses the synthesis and characterization of PVP-b-PVAc block copolymers. The 
physicochemical properties relating to their potential as drug carriers for hydrophobic anti-cancer 
drugs are described.  
Chapter 4 Poly(vinylpyrrolidone)-b-poly(vinyl acetate): A potential drug carrier 
The encapsulation of a model drug (clofazimine) and a common anti-cancer drug (paclitaxel) 
into PVP-b-PVAc aggregates is reported. The drug-loaded PVP-b-PVAc are characterized 
regarding particle size, morphology, stability and drug loading capacity in order to assess their 
feasibility as a drug carrier. 
Chapter 5 In vitro cytotoxicity and cellular uptake of PVP-b-PVAc 
In vitro cytotoxicity and cellular uptake of the PVP-b-PVAc carrier are presented and discussed. 
Chapter 6 Summary and Perspectives 
The chapter provides a summary of the work described in this dissertation. Suggestions for 
future research for the development of PVP-b-PVAc block copolymers for anti-cancer drug 
delivery are also presented. 
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Chapter 2 Historical and theory 
 
2.1 Introduction 
The application of natural and synthetic polymers for medical purposes has been an area of great 
interest over the last decade in biomedical research.1 Synthetic polymers are ideal tools for 
biomedical applications because they can be highly tailored in terms of composition and 
architecture.  
 
In the 1990s, the use of polymer-based drugs and drug delivery systems emerged as a potential 
strategy in the treatment of various life-threatening diseases.2 As a result of the rapid 
development in nanotechnology, the use of polymeric nanoparticle systems has shown potential 
use in drug delivery systems, more specifically in drug solubilization, controlled drug release and 
drug targeting. These “nanopharmaceuticals” are considered as first generation medicines and 
contribute to the improvement in the treatment of genetic and life-threatening diseases.3,4  
 
Polymers applied in drug delivery systems are divided into two main classes namely the 
covalently linked polymer-drug conjugates and non-covalently, self-assembled conjugates. 
Covalently linked conjugates are polymer-drug conjugates where the polymer is covalently 
linked to the drug by a cleavable bond. Self-assembled, colloidal drug carrier systems include 
polymeric nanoparticles, micelles, vesicles, liposomes, viruses (viral nanoparticles), and 
organometallic compounds (nanotubes) in which the drug is physically entrapped (non-
covalently bound) to the polymer. These self-assembled structures differ in terms of their particle 
size (10 nm – 1 µm) and morphology (Figure 2.1). The various drug delivery systems - polymer-
drug conjugates, polymer-protein conjugates, and colloidal drug delivery systems are collectively 
termed as “polymer therapeutics”.2 
 
 
 
 
 
1 nm                      10 nm                       100 nm                      1 µm 
dendrimers 
  micelles 
vesicles 
nanogels 
liposomes 
Figure 2.1: Particle sizes of various colloidal drug carrier systems 
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2.2 Controlled radical  polymerization 
In the mid 1970s, Ringsdorf and coworkers proposed a model for drug delivery. However, 
during those times the control of polymer architecture, molecular weight and molecular weight 
distribution was an obstacle, which limited their ability to develop well-tuned drug delivery 
vehicles.5,6 Controlled radical polymerization (CRP) was developed in the recent past as an 
answer to the increasing demand for new materials with controlled properties. This concept is a 
valuable approach to provide a large range of polymers with well-defined molecular 
characteristics (length, composition and architecture) under not very demanding conditions. The 
development of CRP therefore, now allows for control over several necessary design criteria for 
well-tuned drug delivery systems. CRP techniques include Nitroxide-mediated Polymerization 
(NMP), Atom Transfer Radical Polymerization (ATRP), Reversible Addition/Fragmentation 
chain Transfer (RAFT), Macromolecular Design via the Interchange of Xanthate (MADIX), 
Organotellurium-mediated radical polymerization (TERP) and Cobalt-mediated radical 
polymerization (CMRP). These techniques are CRP techniques that are currently most popular 
and are being used to control polymer molecular weight, polymer compositions, polymer 
topologies, and functionalities. 
 
2.2.1 RAFT/MADIX-mediated polymerization 
In the late 1990s, the concept of RAFT/MADIX-mediated polymerization was first reported. The 
CSIRO group reported on the use of thiocarbonyl thio compounds such as dithioesters, 
trithiocarbonates and dithiocarbamates as chain transfer agents7,8 (CTAs) while Zard’s group 
claimed the term MADIX, for the use of xanthates as CTAs.7,9,10  
 
MADIX proceeds via an identical mechanism as the CSIRO-reported RAFT process. The 
elementary steps of initiation, propagation and termination are present in the mechanism. The 
important equilibrium step is illustrated in Scheme 2.1. Rapid equilibrium between the active 
propagating radicals (Pm  and Pn ) and the dormant species end-capped with the CTA ensures 
equal probability for chains to grow. The mechanism is well documented in the literature and 
will therefore not be discussed in detail.10,11 
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Scheme 2.1: Main equilibrium of the RAFT process 
 
2.2.2 Xanthate-mediated synthesis of poly(N-vinylpyrrolidone) (PVP) and poly(vinyl acetate) 
(PVAc)   
PVP is an attractive water-soluble and biocompatible polymer and has been extensively used in 
pharmaceuticals, cosmetics, foods, printing inks, textiles, and many more diverse applications. 
PVAc is a water-insoluble polymer and it is used in applications ranging from adhesives, paints, 
concrete additives to pharmaceuticals. CRP of most conjugated monomers has shown to be very 
effective, however for non-conjugated monomers, such as VAc12,13 and NVP, CRP is more 
challenging. The limited success to control these monomers is speculated to be due to the high 
reactivity of the chain-end radicals which are prone to side-reactions resulting in dead polymer 
chains.14 
 
NVP can be polymerized by conventional radical polymerization to high molecular weight. CRP 
techniques such as ATRP,15 NMP16 and organostibine-mediated polymerization17 have been 
reported for the CRP of NVP. Xanthates have also been identified as being suitable for 
polymerization of NVP resulting in narrow molar mass distributions. The group of Kamigaito 
and Okamoto published the first paper on xanthate-mediated polymerization of NVP.18 Since 
then, other xanthates have been reported. Pound et al.19 conducted a detailed study on NVP 
polymerization using various O-ethyl xanthates with different R groups including PEG-based 
chains. The results showed good control of the molecular weight with narrow molar mass 
distributions. 
 
The synthesis of PVAc with controlled molecular weight and functionality has become an 
attractive goal. Although there has been limited success for the control of PVAc, several studies 
in the literature have reported on the use of CRP of VAc. CRP techniques for VAc include 
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MADIX/RAFT,20-22 iron-catalysed,23 cobalt-mediated,24,25 organotellurium and organostibine-
mediated polymerization.26 Successful control of VAc polymerization has only been reported 
using xanthates as mediating agent under a RAFT mechanism.20 
 
Many researchers have reported the use of CRP for the synthesis of well-defined block 
copolymers and (end) functional polymers producing synthetic biomaterials and therapeutics.6 
Amphiphilic block copolymers consisting of a hydrophilic monomer, (e.g. NVP) and a 
hydrophobic monomer (e.g. VAc) have been reported previously. The first examples of block 
copolymers containing a PVP block prepared via CRP were reported recently, with the syntheses 
of poly(styrene)-b-poly(N-vinylpyrrolidone) and poly-(methyl methacrylate)-b-poly(N-
vinylpyrrolidone) via organostibine-mediated polymerization.27 Matyjaszewski et al.28 studied 
CMRP for NVP and VAc. The results showed poor control for NVP compared to VAc, however, 
statistical PVAc-co-PVP copolymers were synthesized in a controlled manner. Debuigne and 
coworkers showed the polymerization of NVP using VAc macroinitiators of different chain 
lengths.29 NVP was effectively initiated by various PVAc macroinitiators and well-defined 
amphiphilic block copolymers (molecular weights 40 000 – 60 000 g/mol, Đ = 1.4 – 1.5) were 
synthesized by CMRP. Recently Fandrich et al.30 synthesized amphiphilic block copolymers 
consisting of PVP and PVAc via a xanthate-mediated polymerization system. PVP macroinitiator 
was synthesized using S-2-propionic acid O-ethyl xanthate and further used for chain extension 
with VAc. Random copolymers of P(VP-co-VAc) instead of well-defined PVP-b-PVAc block 
copolymers were obtained. Their results indicated that side reactions during RAFT 
polymerization have a strong influence over the control of the molar masses of the block 
copolymers.  
 
The study presented in this dissertation focuses on the use of PVP-b-PVAc block copolymers as 
potential drug carriers. CRP is therefore favorable and advantageous as it allows one to tailor-
make polymers to fulfil the requirements for a suitable drug carrier system. However, in order to 
design a drug carrier, it is necessary to understand the requirements for the polymers to be used. 
In the section to follow, an overview of drug carriers mainly polymer micelles and vesicles will 
be given. 
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2.3 Amphiphilic block copolymers in anti-cancer drug delivery  
Chemotherapy has been a prominent and common way for treating cancer. However, there are 
several obstacles that make chemotherapy challenging. Many therapeutic compounds are 
available as drug candidates but one third of them are poorly water-soluble making delivery of 
these agents to targeted sites challenging.31,32 Furthermore the inability to deliver adequate doses 
of anti-cancer drugs to tumors in the body is a major obstacle in chemotherapy. The high toxicity 
of these drugs limits their dose which is required in order for the treatment to be effective.33 
Various drug delivery systems based on polymeric nanomaterials are currently under 
development in biomedical research in order to reduce toxicity, to minimize drug degradation 
and loss upon intravenous administration, to prevent harmful side effects and to increase the drug 
bioavailability. Several methods are available to improve the solubility of these hydrophobic 
agents and simultaneously act as drug carrier for drug delivery.34 One of the most widely used 
drug delivery systems are amphiphilic block copolymers that have the ability to self-assemble in 
aqueous environment to form polymer micelles or vesicles.35 A few examples have been briefly 
described in Table 2.1 with each method having its own advantages and disadvantages. 
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Drug carrier Structure    Advantages Disadvantages 
 
Polymer-drug 
conjugates     
 
 
 
 
 
Drugs are 
conjugated 
to the side chain of 
a linear polymer via 
a labile bond 
Administered by 
injection or infusion 
 
Multifunctionality 
 
Polymer backbone can 
be modified by adding 
targeting ligands or 
imaging agents 
 
 
Chemical modification of 
drug could result in loss of 
bioactivity of the drug 
 
Only drugs with reactive 
side groups are potential 
candidates 
 
 
Polymer micelles / 
Polymersomes 
(vesicles) 
 
Amphiphilic block 
copolymers 
assemble and form 
micelles/vesicles in 
aqueous 
environment  
 
 
Administered by 
injection or infusion  
 
Well defined structures. 
Chemical composition, 
molecular weight and 
block length ratios can 
be tailored, allowing  
control of the size and 
morphology 
 
Targeting potential 
-Active and passive 
targeting  (EPR effect) 
 
Suitable carrier for 
water-soluble/insoluble 
drug (or multiple drugs 
in the same carrier) 
 
Variety of techniques 
can be used to 
encapsulate drug 
 
Ease of functional 
modification => control 
and stimuli-response 
drug release 
 
 
 
Often limited loading 
capacity and efficiency 
 
Difficulty in transporting 
through cell membrane 
 
Instability in aqueous 
environment and in the 
presence of blood 
components 
 
Liposomes Self-assembled 
colloidal 
structures made 
of lipid bilayers 
Administered by 
injection or infusion  
 
Targeting potential 
 
Ease of modification 
Often limited loading 
capacity 
 
Instability in the 
presence of blood  
components 
 
Table 2.1: Various drug delivery carriers for the solubilisation and delivery of therapeutic agents 
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2.3.1 Amphiphilic block copolymers as drug delivery carriers 
In the 1970s Ringsdorf was the first to report on the idea of the application of block copolymer 
micelles for sustained release of drugs in drug delivery.36,37 In their approach, the drug was 
covalently linked to one of the blocks of the copolymer via a cleavable linkage. In the late 1980s 
the concept termed “micellar microcontainers” was introduced by the group of Kabanov.38 In 
their approach, the drug was non-covalently fixed in the hydrophobic core of block copolymers 
micelles. Thereafter, much research has been reported by the groups of Kataoka and Kabanov on 
‘micellar microcontainers’. To date, it has become the preferred strategy in drug delivery.39 
 
2.3.2 Amphiphilic block copolymer micelles and vesicles 
In aqueous solution, AB block copolymers consisting of both a hydrophilic and a hydrophobic 
block self-assemble into distinct nano-sized structures which range between 10 – 200 nm. The 
micellar aggregates can adopt different morphologies, such as spherical, rod-like, core-corona, 
vesicle, and worm-like micelles depending on the length of the hydrophilic and the hydrophobic 
segments, the solvent system and the preparation method (Figure 2.2).40,41  
 
 
 
 
 
 
 
Figure 2.2 TEM images illustrating the effect of block length on the morphology of micelles: a) vesicles 
from an aqueous solution of the diblock copolymer PS240-b-PEO15 b) rodlike and spherical structures 
from an aqueous solution of the diblock copolymer PS240-b-PEO8042 
 
Spherical micelles are made up of a hydrophilic outer corona and an inner hydrophobic core as 
illustrated in Figure 2.3. The micelles are structured in a way that the outer corona of the micelle 
is made up of components that are unreactive towards the blood or tissue components. The 
corona of the micelles acts as a protective shell that prevents hydrolysis and enzymatic 
degradation of the drug during transport. It also prevents the drug from being  
A B 
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recognized by the reticuloendothelial system (RES) (a class of cells responsible for clearing 
foreign substances and pathogens from the bloodstream) thereby prolonging the circulation time 
of the drug in the bloodstream. The hydrophobic core acts as a reservoir in which the 
hydrophobic drug or multiple drugs43 can be loaded and carried to the target site. For example, 
paclitaxel (PTX) is a poorly water-soluble anti-cancer drug. To improve the drug solubility, 
surfactant or solvent (such as an ethanol/cremophor mixture for PTX) is normally used in 
combination with these drugs.44 However, most surfactants and solvents are not fully 
biocompatible. They are toxic to the human body and result in undesirable side-effects. 
Therefore, the use of polymer micelles to improve the solubility of the drug (replacing the toxic 
solubilising agent and thus allowing administration of higher doses), is an alternative approach. 
Soga et al.45 showed that the water solubility of the anti-cancer drug PTX, increased from 0.0015 
mg/mL to 2 mg/mL by the encapsulation into a polymer micelle. This is an important 
improvement in drug delivery as it increases the availability of the drug for action within the 
tumor. Furthermore it allows the drug to be administered, transported and delivered more 
effectively to the desired area through the bloodstream which is mostly comprised of water. 
Several anti-cancer drugs and polynucleotides have been effectively solubilised by polymeric 
micelles and have demonstrated superior properties and lower toxicity compared to free drugs. 
 
 
 
 
 
 
 
 
Polymer micelles can also be functionalized to improve the physicochemical and biological 
properties of the self-assembled drug carriers. Substituents can be attached to both hydrophobic 
and hydrophilic segments in order to start crosslinking in the core or corona region respectively. 
The second use of substituents might be to enhance the functionality of the micelle surface. 
Furthermore, the micelles can be chemically modified without changing the physicochemical 
Hydrophobic inner core 
Figure 2.3: Schematic representation of polymer micelles43 
10 – 200 nm   
Aqueous environment        
[unimer] > CMC 
Amphiphilic block copolymer 
“unimers” and free drug   
 Hydrophilic outer shell   
 
Hydrophobic drug 
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properties of the micelles, which makes them unique and “superior” over other drug carrier 
systems.46  
 
Polymer vesicles have attracted increased attention in recent years due to their similarity to 
liposomes. Compared to liposomes that are composed of low molecular weight phospholipids or 
surfactants, vesicles are based on high molecular weight amphiphilic block copolymers.34 
Polymer vesicles are hollow, lamellar spherical structures with a hydrophilic surface a 
hydrophobic membrane and an aqueous interior as illustrated in Figure 2.4. Like micelles, 
vesicles also have a wide range of morphological variations (e.g. onion-like vesicles, elongated 
tubular vesicles and large compound vesicles, flower-like vesicles).47 They range in diameter 
from 0.1 – 1 µm and consist of a bilayer membrane having physical and chemical stability which 
is advantageous for many applications such as drug delivery.48 
 
 
 
 
 
 
 
Figure 2.4: TEM image (left) and schematic representation (right) of a polymer vesicle49 
Unlike polymer micelles, which are mostly used for loading hydrophobic drugs (having only a 
hydrophobic core), vesicles are capable of being loaded with both hydrophilic drugs (within the 
aqueous interior) and hydrophobic drugs (in the bilayer membrane). The bilayer membrane 
provides a physical barrier that isolates the encapsulated molecules from the external 
environment. In recent years, combination therapy whereby a combination of multiple drugs as 
opposed to a single drug are used for cancer treatment has gained significant interest. The 
synergistic effects of cancer drugs has been extensively investigated and has found great 
success.50 Ahmed et al.51 used PEG-b-PLA and PEG-b-polybutadiene (PEG-b-PBD) for the 
delivery of two anticancer drugs. The relatively hydrophilic drug doxorubicin (DOX) was 
located in the lumen, whereas the hydrophobic drug paclitaxel (PTX) was entrapped in the 
bilayer. In vitro experiments showed that after one day, 80 % of DOX and 60 % of PTX were 
Hydrophilic  
Hydrophobic 
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released from the vesicles. In vivo studies on human breast tumors in nude mice showed that 
higher concentrations of drug could be administered for the DOX and PTX-loaded vesicles 
compared to the free drug cocktail. Eisenberg and co-workers synthesized DOX-loaded vesicles 
that were able to release the drug at a slower rate (30 % in 5 minutes) and in a controlled manner 
compared to free DOX (80 % in 5 minutes).52  
 
2.3.3 Active and passive drug targeting 
The application of amphilphilic block copolymers as drug carriers is advantageous in that they 
are able to solubilise hydrophobic drugs and be used in passive and active targeting. Polymer 
drug carriers such as micelles and vesicles have shown to target tumors through passive 
accumulation through the enhanced permeation and retention (EPR) effect. This concept was 
coined by Maeda et al. in 1989.53 The EPR effect (Figure 2.5) explains the mechanism through 
which the drug carrier accumulates in the tumor tissue for prolonged times by taking advantage 
of the leaky vasculature.54 Tumor cells have large leaky vasculature with poorly aligned 
epithelial cells with wide openings. This enables the micellar drugs to become trapped and 
accumulate within the tumor due to impaired lymphatic drainage at these areas. Simultaneously, 
extravasation of the drug-loaded micelle or vesicles in normal healthy tissue is decreased, 
compared to low molecular weight drugs, which extravasate in various tissues and are easily 
removed from the body via renal clearance, resulting in toxicity to the kidneys. The size of the 
tumor vasculature is dependent on the age and the type of tumor, having a pore size from 0.1 – 
2µm.55 On the other hand, active targeting is achieved by the attachment of targeting ligands to 
the micelles or vesicles so as to be recognized by cell receptors for binding. In these cases, the 
likelihood that the drug-loaded micelle or vesicle will reach the tumor and be internalized by the 
cancer cells is greater. Folate receptors are often used for active targeting of cancerous tumor 
sites.56-58  
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2.3.4 Inherent size of polymer drug carriers and the biodistribution of the drug 
The polymer drug carrier size and biodistribution of the drug is one of the determining factors of 
the drug carrier efficacy. The size of the carrier is dependent on a number of variables including 
the molecular weight of the copolymer and the length of the hydrophilic and hydrophobic 
blocks.59 For passive drug targeting, the polymer carrier size should range from 10 – 200 nm. 
These sizes are desirable in order to avoid renal excretion (< 10 nm), to prolong the circulation in 
the bloodstream. This avoids RES elimination (> 200 nm)60 and allows for selective tumor 
accumulation based on the EPR effect.33,61 The EPR effect is observed for macromolecules with 
molecular weights greater than 20 kDa. In recent years, most research groups selected polymer 
drug carriers with molecular weights in the range of 20 to 200 kDa. The renal excretion limit is 
less than approximately 20 – 40 kDa.62 The molecular weight of the polymer micelles is usually 
higher than this limit, making them difficult to be removed via renal clearance. It is, therefore, 
assumed that only when the micelles fall apart through degradation or dilution, the copolymer 
unimers could be eliminated via renal excretion. Opsonization is a process whereby proteins 
adhere to the drug carrier when intravenously administered.63 This results in the drug being 
released from the carrier and also in elimination of the carrier by the mononuclear phagocytic 
system (MPS). These are phagocytic cells that recognize certain proteins on the surface of the 
carrier and remove them from the bloodstream. The size and the surface properties of the 
  
 
 
 
 
  
 
 
 
   
       
    
  
 
 
 Bloodstream 
Normal tissue 
Drug loaded micelles or vesicles 
Leaky tumor tissue 
  
Tumor cells 
Drug release from micelles 
Figure 2.5: Schematic representation of the EPR effect- the nonfunctionalized micelles or vesicles 
extravastate in the leaky tumor vasculatures 
Stellenbosch University http://scholar.sun.ac.za
Chapter 2 Historical and theory 
 
 19 
polymer drug carrier, therefore, influence the extent of opsonisation and further influence the 
biodistribution and pharmacokinetics of the polymer drug carrier.  
 
2.3.5 Hydrophilic corona and hydrophobic core components of polymer drug carriers 
PEG is a water soluble, biocompatible polymer with low toxicity and immunogenicity. It is 
undoubtedly the most frequently used hydrophilic polymer in amphiphilic block copolymers for 
drug delivery application. Recently, it was shown that PVP is a viable alternative for PEG.64 PVP 
is a well known water-soluble, biocompatible and relatively amphiphilic polymer. In selected 
applications, PVP has been shown to have superior properties compared to PEG. Research has 
shown that a tumor necrosis factor (TNF) conjugated to PVP shows a higher anti-cancer activity 
compared to that of the corresponding PEG conjugate.65 Mayumi et al. also found a PVP-TNF-α-
conjugation was a more potent antitumor therapeutic agent than PEGylated TNF-α.65 PVP-based 
drug carriers have also shown to improve the plasma half-life of drugs.66 Recently it has been 
reported that PVP is able to prevent protein absorption.67 Several amphiphilic PVP-based block 
copolymers have been reported, for example block copolymers with poly (ε-caprolactone) 
(PCL), 68 poly(N-isopropyl acrylamide) (PNIPAM), 69 poly (D,L lactide) (PDLLA)67 and 
poly(styrene) (PSty).70  
Due to the large number of hydrophobic drugs available, several hydrophobic polymers as core 
forming segments have been investigated. The hydrophobic core of micelles or bilayer 
membrane of vesicles acts as a reservoir in which the hydrophobic drug is solubilized and the 
affinity for the drug and the hydrophobic polymer determines the degree of solubilization. In 
order for selective drug accumulation to take place, leakage of the drug from the micelles or 
vesicles and early release of the drug need to be prevented. Therefore, the overall stability, the 
drug loading capacity and the drug release profile are dependent on the hydrophobic block. 
Examples of frequently used hydrophilic and hydrophobic polymers used are presented in Table 
2.2. The encapsulation of commonly used anticancer drugs such as PTX,68,71 DOX,72-74 and 
indomethacin75 into these hydrophobic core forming blocks has been well documented in the 
literature.  
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Hydrophilic polymer Abbreviation Chemical structure 
Poly(ethylene glycol) PEG75,76 
 
 
Poly(N-vinyl pyrrolidone) PVP77-79 
 
Poly(acrylamide) 
 
 
 
 
 
 
PAM49 
O
NH2
n
 
 
 
Hydrophobic polymer Abbreviation      Chemical structure      
   
Poly (lactic) acid PLA80,81 
 
Poly(ε- caprolactone) PCL76,79,82 
 
Poly(N-isopropyl 
acrylamide) 
PNIPAM83,84 
 
Poly(β-L-benzyl aspartate) 
Poly(benzyl-L- glutamate) 
PBLA85,86 
PBLG87 
 
 
 
OH
O
H
n
N O
n
O
O
O
n
O
O
O
n
O
NH
n
O
R
O
O
NH
n
R = CH2 or C2H4
Table 2.2: Selection of hydrophilic and hydrophobic polymers often used for the preparation of micelles 
or vesicles as drug carriers 
drug delivery 
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2.3.6 Stability of polymer drug carriers in aqueous and biological environment 
In a selective solvent, block copolymers self-assemble into ordered structures (e.g. micelles or 
vesicles) via a so-called closed association process, above the critical micelle concentration 
(CMC). Below the CMC (i.e. at very low concentrations), the polymers only exist as single 
chains (unimers).39 Above the CMC, micelles are in equilibrium with the unimers. The CMC of 
polymer micelles are generally  10-6  – 10-7 M.39 Therefore, dissociation of the drug carrier 
occurs at very low concentrations. This is essential for drug delivery, because the micelles are 
subject to dilution upon intravenous administration and have to maintain the micellar form for 
prolonged circulation in the bloodstream.88  
 
Polymer micelles can be considered as thermodynamically stable (the potential of disassembly) 
or kinetically stable (the rate of disassembly). The thermodynamic stability is dependent on the 
length of the hydrophobic block, and inversely related to the CMC (for instance an increase in 
the hydrophobic block length, decreases the CMC and increases the thermodynamic 
stability).49,89 The kinetic stability refers to the rate at which dissociation of the micelles into 
unimers occurs. The kinetic stability is dependent on both the hydrophilic and the hydrophobic 
block, but the nature of the hydrophobic block has a more profound impact.38,90,91 Based on the 
theory of micellization, other factors such as the nature of the hydrophobic block (being more or 
less hydrophobic) and the hydrophilic block (neutral vs. charged), block length, polymer 
concentration, and molecular weight may also affect the size, morphology and the stability of the 
resulting carrier. It has been reported that the encapsulation of drugs can enhance the stability of 
the micelles.92  
 
Although the potential of block copolymer micelles or vesicles as carriers in drug delivery are 
foreseen, the clinical application is limited until now. This is due to the large dilution effect, 
which causes micelle or vesicle destabilization in the bloodstream. Polymer concentrations drop 
below the CMC, which results in the collapse of the micelle or vesicle structures.93,94 In addition, 
serum albumin, enzymes and other proteins present in the bloodstream have also shown to 
interact with the carriers, affecting the stability.93,95-97 Garreau et al. reported evidence that 
proteins possibly penetrate into the hydrophilic shell of PEG-b-PCL block micelles resulting in 
their degradation.98 
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Förster resonance emission transfer (FRET) microscopy is often used to monitor the stability of 
micelles in real time after intravenous injection. Chen et al.99 used this technique to show that 
PEG-b-PDLLA micelles were unstable in the blood. Recently Lu et al.100 reported on the 
stability of (D,L-lactide-co-2-methyl-2-carboxytrimethylene carbonate)-g-poly(ethylene glycol), 
P(LA-co-TMCC)-g-PEG, in the presence of all the major proteins present in serum using FRET. 
 
One way to increase the biological stability of the drug carrier (and subsequently prolong the 
circulation time in the blood) is by the presence of a high surface coverage of hydrophilic chains 
on the surface of the carrier. As mentioned previously, the hydrophilic corona is responsible for 
the stability of the carrier. The extent to which the corona can stabilise the carrier depends on the 
surface density and the thickness of the hydrophilic shell. Several publications have shown that a 
high coverage of PEG on surfaces enhances the circulation longevity of carriers by reducing 
interactions with plasma proteins and cell-surface proteins.101 Recently, PVP has come to be 
recognized as effective in resisting non-specific protein adsorption.102,103 Numerous other 
approaches are starting to emerge in aiming to improve the stabilization of drug-loaded polymer 
carriers under physiological conditions. For example, in the case of micelles, strategies such as 
the introduction of strong hydrophobic interactions or hydrogen bonds in the micelle cores, core-
crosslinking, shell-crosslinking and waist-crosslinking micelles have been undertaken to improve 
the stability of micelles.104-108 However, cross-linked micelles do suffer from several drawbacks, 
one being non-biodegradability and difficulty of the cross-linked micelles to be eliminated from 
the body.109 Similar approaches have also been applied to vesicles in which crosslinking the 
bilayer structure of the vesicle membrane further improves the stability.110The subject of cross-
linked micelles and vesicles shall not be addressed in this chapter and the reader is referred to the 
above references for more information. 
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2.4 Preparation and drug loading into polymer drug carriers 
2.4.1 Drug loading methods for polymer micelles and vesicles 
Hydrophobic drugs can be incorporated into micelles or vesicles by chemical conjugation, 
physical entrapment or polyionic complexation. Chemical conjugation implies the formation of a 
covalent bond between a chemical group on the drug and one on the hydrophobic block  
of the block copolymer via a biodegradable, pH- or enzyme-sensitive linker. Upon exposure to 
the right trigger, release of the drug into the cells takes place. Despite the advantage that the drug 
is stably retained in the hydrophobic domain, this technique suffers from several drawbacks. 
Drug molecules and polymer do not always contain reactive functional groups. Specific block 
copolymers, therefore, need to be synthesized for a specific drug in order to allow chemical 
conjugation. In addition, chemical modification of a drug could result in alteration or loss of its 
bioactivity. Polyionic complexation involves the use of charged therapeutic agents (e.g. 
polynucleic acids) which are incorporated through electrostatic interaction with the oppositely 
charged ionic segment of the block copolymer.111 
 
In most cases, the preferred method for the incorporation of a drug into polymer is by physical 
entrapment. A variety of drugs can be encapsulated in the hydropohobic core of micelles or the 
hydrophobic bilayer membrane of vesicles, irrespective of the chemical structure of the drug and 
the chemical structure of the block copolymer. The encapsulation of multiple drugs is 
advantageous in that synergistic effects of cancer drugs have shown promising results from 
multiple clinical trials.50 Commonly used preparation and drug loading methods via physical 
entrapment are dialysis, oil-in-water (o/w) emulsion, solvent evaporation, solution casting and 
freeze drying. These methods are briefly described below. It must be mentioned that depending 
on the polymer system, each method can yield varying self-assembled structures (spherical 
micelles, rod-like micelles, flower-like micelles, vesicles etc.). Factors such as the length of the 
individual blocks, the nature of the solvent, the water content and the preparation method, all 
provide control over the types of self-assemblies formed.112 
 
• Dialysis method 
In this study, the dialysis method was implemented. In the dialysis method, the polymer and the 
hydrophobic drug are dissolved in a water-miscible organic solvent such as dimethylsulfoxide 
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(DMSO), dimethylformamide (DMF) or tetrahydrofuran (THF).61 The homogeneous solution is 
then dialysed against distilled deionised water. The gradual replacement of the organic solvent 
with water (non-solvent for the hydrophobic block) allows for the self-association of block 
copolymers and the entrapment of the drug in the  
 
hydrophobic core. Provided that the molecular weight of the polymer is high enough (i.e. the 
molecular weight cut off (MWCO) of the dialysis tube is not too high), the dialysis membrane 
keeps the micelles or vesicles inside the dialysis tube, but allows the removal of solvent and 
unloaded free drug. Figure 2.6 illustrates this procedure 
 
 
 
 
 
 
 
 
Literature studies have shown that the size of the self-assembled block copolymers is dependent 
on the organic solvent chosen in this method.61,113 For example, La et al.85 used the dialysis 
method in their micelle system of PEO-b-PBLA and studied the effect of the organic solvents 
DMSO and N,N-dimethylacetamide (DMAc) on the particle size of the micelles. The results 
obtained showed a difference in the particle size depending on the solvent used. Consequently, 
the dialysis method is advantageous as it can be used to modify the properties of the micelles for 
their specific application. 
• Oil/water emulsion method 
The polymer and the drug are dissolved in a water-immiscible organic solvent followed by the 
addition of water. The mixture is then sonicated or stirred vigorously leading to the formation of 
nano-sized droplets within the aqueous phase. The organic solvent is then removed by 
evaporation resulting in drug-loaded micelles or vesicles.61,85,114 
 
 
dialysis Amphiphilic block copolymer and drug in 
solvent 
Polymer micelle or 
vesicle  
Figure 2.6: Illustration of the dialysis method for drug encapsulation into resulting in drug-loaded 
micelles or vesicles 
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• Solvent evaporation method 
This method is based on dissolving the drug and the polymer in an organic solvent followed by 
the removal of the solvent leading to the formation of a film. The film is then reconstituted in the 
aqueous phase. This method is however limited to block copolymers having high hydrophilic 
lipophilic balance (HLB) values such that the polymer film can easily dissolve in aqueous 
media.61,82 
 
• Freeze drying method 
The freeze-drying method has been reported and appears to be effective for PVP-based block 
copolymers. The polymer and the drug are dissolved in water and a solvent (e.g. tert-butyl 
alcohol). The mixture is frozen and the aqueous phase removed via freeze-drying. The solid 
polymer cake is then dissolved in a medium such as an aqueous sodium chloride or dextrose 
solution, forming drug-loaded micelles.61,115 The freeze-drying method has been used for the 
encapsulation of PTX and its derivatives in PVP-b-PDLLA block copolymers.91,116 
 
2.4.2 Factors affecting the drug loading 
In order to limit the toxicity and the undesirable side-effects that can arise from the drug carrier, 
the loading efficiency is crucial. Furthermore, minimising the overall costs of the formulation is 
also important. There are several factors that affect the drug encapsulation which will be 
discussed briefly. 
 
Drug loading is a process of solubilising drug in a polymer matrix. The mechanism of drug 
loading can therefore be explained in terms of solubility parameters. An important factor that 
controls the drug loading content is the drug-core compatibility. The Flory-Huggins interaction 
parameter can be used to predict and to quantify the compatibility between the polymer and drug. 
 
The Flory-Huggins interaction parameter, χdp, between the drug and the polymer is expressed 
as:117 
χdp = ( δd  - δp )2 

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where δd and δp are the Scatchard-Hildebrand solubility parameters of the drug (d) and the core 
forming polymer (p) respectively,
 
  is the molecular volume of the drug , R is the ideal gas 
constant and  the absolute temperature. It is expected that the lower the interaction parameter, 
the greater the compatibility between the drug and the core forming polymer. The higher the 
compatibility, the higher the loading capacity. 
 
Interactions between the drug and hydrophilic block can also influence the loading capacity. 
Benahmed et al.78 showed that block copolymers of PVP-b-PDLLA showed higher drug loading 
efficiency than PEG-b-PDLLA micelles. This might be due to the binding of the drug (i.e. 
indomethacin) to PVP probably via intermolecular hydrogen bonding between the drug hydroxyl 
and PVP carbonyl groups. The length of both the hydrophobic and hydrophilic blocks also are an 
important factor.118 In the first case, the longer the hydrophobic block, the larger the hydrophobic 
domain and domain-space available, therefore, higher amounts of hydrophobic drug can be 
entrapped resulting in higher drug loading. In the second case, increasing the length of the 
corona hydrophilic block increased the CMC. Therefore, a smaller fraction of the polymer will 
be present in micellar/vesicular form in aqueous solution. This results in a decrease in the 
hydrophobic regions thus, the total amount of drug encapsulated. Letchford et al.119 studied the 
effect of the hydrophobic block length of PEG-b-PCL micelles on the drug loading capacity. 
Longer PCL blocks resulted in higher drug loading. An increase in the hydrophobic core 
segment resulted in an increase in the partition coefficient resulting in an increase in loading 
capacity. The entrapment efficiency can also depend on the initial amount of drug to be 
solubilised. Incorporation of large amounts of drug into the micelles or vesicles can result in 
precipitation of the drug and reduce the loading yield.120 The localization of the drug molecules 
in the micelles also plays an important role. For example, in drug-loaded micelles it is often 
assumed that the drug is only incorporated in the hydrophobic core. However, the drug can be 
incorporated in either the corona, the hydrophobic core or at the interface of the corona-core, 
which would influence the loading capacity.61 
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2.5 Drug release and cellular internalization of polymer drug carriers 
2.5.1 Drug release 
Drug release from the polymer drug carriers for drugs that have been encapsulated via physical 
entrapment occurs by diffusion. One of the challenges in polymer-based drug delivery is the 
ability to control the drug release kinetics. Polymeric self-assembled structures, for example, can 
release more than 50 % of the encapsulated drugs within the first several hours due to the so-
called “burst effect.”121 This could be problematic as the carrier needs sufficient time to reach the 
targeted tumor and deliver the drug (without any premature leakage of the drug from the carrier) 
to the desired site. The release is controlled by the rate of diffusion of the drug from the drug 
carrier, the stability of the drug carrier, and the rate of degradation of the block copolymer. 
 
In order to achieve effective drug targeting, the drug must reach the target site intact and 
selectively be released from polymer micelles or vesicles at the targeted site. Drug-loaded 
polymer carriers should, therefore, have sufficient stability in the blood stream. Fast release of 
drugs from polymer micelles or vesicles can result in precipitation of the hydrophobic drug in the 
body and allow insufficient time for polymer micelles or vesicles to accumulate at the target site. 
On the other hand, slow drug release allows for accumulation of the carrier at target sites with 
minimal drug loss and localized drug release. 
 
Interestingly, the release rate of a drug from the polymer drug carrier is dependent on several 
factors similar to those affecting the loading capacity and micelle stability, however, having 
opposite effects. The influence of the drug loading capacity, molecular weight and the 
hydrophilic and the hydrophobic block length on drug release behaviour have been well 
documented.122 Other factors affecting the release rate include the compatibility between the 
drug and polymer.118 A strong interaction between the hydrophobic core- or bilayer membrane-
forming block and the hydrophobic drug results in high loading capacity and slow drug release. 
This is due to the stronger interaction between the core or the bilayer and the drug molecules. 
 
The location of the drug within the micelle or vesicle also determines the drug release.61 For 
example, a hydrophobic drug that is present in the corona or at the interface of the corona and 
core of the micelles will be released more rapidly than drug present inside the core. Hydrophobic 
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drug molecules located in the hydrophobic core of micelles will have to diffuse through a longer 
path (larger core radius) resulting in slower release. Release kinetics often display an initial burst 
associated to the fast release of drug molecules located in the shell or at the core-shell interface 
followed by a slow release which corresponds to the diffusion of the drug from the core. The fast 
release can also be attributed to premature micelle disassembly which was confirmed in a study 
conducted by Chen et al.99 
 
The physical state of both the hydrophobic block and the hydrophobic drug can also influence 
the release characteristics. If the glass transition temperature (Tg) of the hydrophobic block is 
above that of the physiological condition (37 °C), the polymer is in solid-like phase or glassy 
state, therefore the diffusion of the drug is expected to be slower.123 Furthermore, crosslinking of 
the hydrophobic core or vesicle membrane could also slow down the drug release from 
micelles.76  
 
2.5.2 Cellular internalization 
After the extravasation into the tumor tissue, the polymer carrier (micelles or vesicles) are 
internalized by the tumor cells (Figure 2.7). It has been observed that polymer carriers cannot 
diffuse through the cell membrane and instead are taken up by cells via a process called 
endocytosis (which is further divided into phagocytosis, macropinocytosis and/or (non) clathrin-
mediated endocytosis).124 Alternatively, in some cases the polymer carrier can release the drug 
close to the region of the cells and the drug can then be taken up by diffusion. 
 
During the endocytosis process, the polymer carrier is internalized by the endosomes, which later 
fuse with lysosomes (Figure 2.7). During endocytosis the pH drops from physiological value (pH 
7.4) to pH 6.5 – 5 in the endosomes and then to pH 4 in the lysosomes. In the acidic environment 
several of the lysosomal enzymes become active (for example nucleases, proteases, lipases).125 
Many studies have shown that the process is complex and details on the mechanism are not yet 
fully understood. To further complicate matters, it has been reported that endocytosis could be 
dependent on the molecular weight of the hydrophobic and hydrophilic blocks, concentration of 
the polymer, particle size of the nanoparticle carrier and the charge of the polymer carrier (which 
could interact with the cell membrane).126,127 
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Increasing efforts have focused on gaining insight into the pathway of cellular internalization. 
Several examples of micelle internalization using fluorescence microscopy have been reported in 
the literature. Yan et al. showed that fluorescently labelled PEG-b-PCL polymer micelles were 
internalized by the cells and then localized in the cytoplasm.128 Musacchio and coworkers 
prepared PEG-PE micelles loaded with paclitaxel.71 Fluorescence images showed that all the 
Rhodamine-PE-labeled micelles were taken up by the living cells already after 3 hours. 
 
The development of intelligent polymeric colloidal carriers for enhanced intracellular drug 
delivery has also been investigated. Most polymer carriers are taken up by endocytosis and the 
pH inside the endosomes are more acidic (pH 5 – 6.5) than that of physiological pH (pH 7.4). 
The intracellular properties can be used for the development of polymer carriers which release 
the drug specifically to the tumor cells. The insertion of acid-cleavable linkages such as 
hydrazones,129 acetals,130 imines131 that hydrolyse easily in the acid environment of the 
endosomes and therefore allow the release of the drug into the intracellular compartments.132  
Figure 2.7: Schematic representation of cellular uptake and release of the hydrophobic drug from the 
polymer carrier 
Cytoplasm 
lysosome 
Endosome pH~ 5 – 6 
Endocytosis 
EPR effect Blood ~ pH 7 
Tumor tissue pH ~ 6.8 
Cell membrane, enlarged tumor cell 
Diffusion of drug into cytoplasm 
nucleus 
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2.5.3 Polymer drug carriers and multiple drug resistance (MDR) 
Cells are able to gain resistance to drugs through a variety of mechanisms such as increased drug 
efflux, enzymatic deactivation and decreased cell permeability.133 However, the use of polymer 
carriers has shown counteracting effects in multiple drug resistance (MDR). The MDR 
mechanism is associated with a number of efflux pumps including P-glycoprotein (P-gp). P-gp is 
a drug efflux transport protein that eliminates drugs from cancer cells and reduces the activity of 
the anticancer drug. Kabanov was the first to demonstrate that PEO-b-PPO copolymers 
(Pluronics) induce inhibition of the P-gp-mediated drug efflux system in cells.134 For example an 
increase in DOX uptake by MDR cells with Pluronics was observed. This is believed to be 
caused by a Pluronic-induced deactivation of drug efflux pumps.135  
Currently, numerous studies on polymer micelles to overcome MDR are being conducted.134,136 
137
 The possible reasoning for polymer micelles to avoid recognition by the P-gp efflux pump is 
by means of the drug being enclosed in an endosome when entering the cell. This further results 
in higher intracellular drug concentrations inside the cells, compared to free drug which is easily 
pumped out.138 The exact mechanism for polymer micelles in conjunction with MDR is not yet 
fully understood. 
 
2.6 Conclusion 
Polymer micelles and vesicles hold promise for the delivery of therapeutic agents. An important 
feature of these drug carriers is their amphiphilic character. Their core–shell or vesicular 
structure and physical properties makes them desirable carriers for hydrophobic drugs to target 
tumor sites in a controlled/triggered fashion. Currently, several polymer drug formulations have 
entered clinical trials with promising results.139,140 However, researchers are faced with many 
challenges and more progress must be achieved to control the stability of the polymer drug 
carriers in vitro and in vivo. Perhaps future research in polymer chemistry and drug delivery will 
eventually lead to the discovery of the “Magic Bullet”, the ideal carrier for targeted drug 
delivery.141 
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Chapter 3 
Synthesis, characterization and self-assembly of poly(N-vinylpyrrolidone)-b-
poly(vinyl acetate) 
 
Abstract  
Amphiphilic block copolymers of constant hydrophilic PVP block length and varying 
hydrophobic PVAc block length were synthesized via xanthate-mediated radical polymerization. 
In order to control the molecular weight of the hydrophilic PVP block, a xanthate chain transfer 
agent, S-(2-cyano-2-propyl) O-ethyl xanthate, was used. The PVP-b-PVAc block copolymer is 
composed of a hydrophilic and hydrophobic segment, which has the ability to self-assemble in 
aqueous solution. The PVP-b-PVAc block copolymers were characterized by 1H NMR 
spectroscopy to confirm self-assembly behavior of PVP-b-PVAc block copolymers in water. The 
critical micelle concentration (CMC) was determined by a fluorescence technique. The CMC 
decreased with increasing PVAc block length, which can be attributed to the greater 
hydrophobicity of the PVAc segment of the PVP-b-PVAc block copolymer. A combination of 
dynamic light scattering (DLS), transmission electron microscopy (TEM) and static light 
scattering (SLS) was used to further characterize the block copolymers in water. DLS showed 
that the average particle size of the self-assembled block copolymers was 180 – 200 nm. The 
morphology of self-assembled PVP-b-PVAc block copolymer in water was examined by TEM, 
which showed spherical vesicles (bilayer-type structures) which was further confirmed by SLS. 
The stability of the PVP-b-PVAc block copolymers was evaluated using DLS under 
physiological conditions (pH 7.4, 37 °C) in the absence and presence of serum. Results showed 
that the block copolymers were stable in physiological conditions. 
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3.1 Introduction 
In recent years, numerous novel drugs have been developed for the treatment of life-threatening 
and genetic diseases. However, these drugs are generally poorly soluble in water, which limits 
their application for intravenous administration.1 As mentioned previously, solubilizing agents 
are often used to solubilize these drugs. However, these solubilizing agents have been associated 
with a number of adverse effects. Furthermore, most of the therapeutic drugs in current clinical 
treatments are small molecules, which generally spread throughout the body in the blood stream 
affecting healthy tissues. In addition, the small molecule drugs can be rapidly cleared by the 
kidneys, thus requiring high doses or continuous infusion for effective treatment. There is thus a 
need for drug delivery systems to overcome the above-mentioned issues. Research has shown 
that the use of drug delivery vehicles allows controlled and sustained delivery of drugs over a 
period of time, which further improves the efficacy of the drug. 
 
Amphiphilic block copolymers have drawn great attention and shown great progress over the 
past years in the field of drug delivery.2-4 Amphiphilic block copolymers consist of hydrophilic 
and hydrophobic segments that self-assemble in aqueous solution. The hydrophobic interactions 
are generally the main driving force behind the micellization process. Dependent on the 
molecular weight and hydrophilic/hydrophobic block ratios, these block copolymers can self-
assemble into various structures such as spherical micelles, cylindrical micelles, worm-like 
micelles, or vesicles.5-7 Discher and Eisenberg presented several studies based on the relationship 
between the block copolymer composition and the self-assembled morphologies.6 They found 
that the self-assembled morphology was most simply a reflection of the hydrophilic-to-
hydrophobic ratio. In their theory, spherical micelles are expected for block polymers with 
hydrophilic mass fraction (f) greater than 45 %, whereas block copolymers with lower 
hydrophilic mass fraction (f) typically self-assemble into vesicles. Many interesting reports have 
also been published on morphology transitions from spheres → cylinders → vesicles (also called 
“polymersomes”), induced by decreasing the relative length of the hydrophilic block.8 
Nevertheless, these self-assembled, nano-sized micelles or vesicles have applications in various 
fields such as water purification,9 surface modification,10 pharmaceuticals and in drug 
delivery.4,11,12  
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For their application in drug delivery, polymeric micelles have a hydrophobic core which can 
provide a depot for hydrophobic guest molecules such as hydrophobic drugs. On the other hand, 
vesicles can accomodate hydrophilic guest molecules in the hollow hydrophilic core and 
hydrophobic guest molecules within the hydrophobic bilayer or membrane. Ideally, these drug 
carriers should have long circulating properties after intravenous administration, without 
premature loss of the encapsulated drug. This allows the drugs to reach the targeted sites 
passively via the enhanced permeation and retention (EPR) effect. Therefore, an important 
property of the amphiphilic block copolymers is the CMC. The CMC of block copolymers is 
usually much lower than that of low molecular weight surfactants.4 This is crucial for application 
in drug delivery as it ensures a good physical stability of the drug carrier against dilution after 
intravenous injection into the blood stream.  
 
The rapid development of controlled radical polymerization (CRP) is increasingly being utilized 
to prepare well-defined homo-, gradient, di- and triblock copolymers for applications in drug, 
protein, and gene delivery for the treatment of infectious and genetic diseases.13 The RAFT 
technique has proven to be a versatile tool for the synthesis of polymers used for drug delivery 
purposes. For the application of polymers in drug delivery, the chemical nature, chain 
architecture, the control of the molecular weight, and hydrodynamic size are important properties 
that contribute towards the stability, the drug loading, drug uptake and drug release of the drug 
carrier system.4 RAFT is a versatile technique for a variety of functional monomers. Hydrophilic 
and hydrophobic monomers with suitable biocompatibility and chain transfer agents with 
reactive functionality further allow for bioconjugation of the polymers to drugs, peptides, 
proteins, targeting moieties and fluorescent dyes.14 The evolution of CRP therefore allows for the 
design and facile preparation of tailor-made polymers for drug delivery applications.14  
 
To date, poly(ethylene glycol) (PEG) is the preferred and most common choice for the 
hydrophilic segment of the amphiphilic block copolymers. In fact, most of the polymer drug 
carriers that have been examined in clinical trials are PEG-based.15,16 However, PVP has shown 
improved properties compared to PEG and is attracting attention as an alternative to PEG.17,18 
PVP is an attractive biomaterial for drug delivery or tissue engineering since it is hydrophilic, 
non-toxic and biocompatible with living tissue. Studies have already shown prolonged in vivo  
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circulation time after intravenous administration for PVP-coated liposomes.19 To date, PVP-
based block copolymers such as PVP-b-poly(D,L-lactide) (PVP-b-PDLLA), PVP-b-poly(ɛ-
caprolactone) (PVP-b-PCL) have been investigated for the self-assembly in micellar structures. 
However, their evaluation for drug delivery both in vitro and in vivo still needs to be explored 
further. 
 
The purpose of the current study was to develop a PVP-b-PVAc drug carrier for hydrophobic 
anticancer drugs. Herein, the synthesis, characterization and self-assembly of amphiphilic PVP-
b-PVAc block copolymers is presented. RAFT/MADIX polymerization was used for the 
synthesis of the block copolymers. PVP-b-PVAc diblock copolymers were synthesized via 
sequential monomer addition as illustrated in Scheme 1. The methodology used in this study 
comprises a two step process. The first step involves the synthesis of a starting block in bulk 
(referred to as the PVP macro-RAFT agent). Bulk polymerization was chosen as it only involves 
initiator, RAFT agent and monomer. Therefore, it minimizes the possibility of contamination and 
results in a high purity starting block. In order to control the molecular weight of the hydrophilic 
PVP block, a xanthate chain transfer agent, S-(2-cyano-2-propyl) O-ethyl xanthate, was chosen. 
In the second step, the starting block (macro-RAFT agent) is chain-extended upon further 
addition of a hydrophobic monomer, vinyl acetate (VAc). After the first step, the majority of the 
chains contain the active RAFT agent on the chain ends, making these potentially active for 
chain extension. Finally, the PVP-b-PVAc block copolymer is composed of a hydrophilic and 
hydrophobic segment, which has the ability to self-assemble in aqueous solution. 
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Scheme 3.1: Two-step reaction procedure for the synthesis of PVP-b-PVAc block copolymers 
 
The self-assembly properties of the block copolymers were investigated using 
1
H NMR 
spectroscopy, fluorescence spectroscopy, transmission electron microscopy (TEM) and light 
scattering techniques. These results can provide useful insight regarding the drug loading 
potential and hence the feasibility of PVP-b-PVAc block copolymers as a drug delivery vehicle 
for hydrophobic anti-cancer drugs.  
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3.2 Materials and methods 
3.2.1 Materials 
N-vinylpyrrolidone (Aldrich, 99 %) was dried over molecular sieves and distilled under reduced 
pressure. Vinyl acetate (Protea Chemicals, 99 %) was distilled under reduced pressure. AIBN 
(Riedel de Haen) was recrystallized from methanol. Dimethyl sulfoxide (Merck, 99 %) was used 
as received. Distilled deionized water was obtained using a Millipore Milli-Q purification system 
and used in all experiments. Phosphate buffer saline (PBS, pH 7.4, sterile) and fetal calf serum 
(FCS, sterile) were obtained from Sigma-Aldrich. 
 
3.2.2 Synthesis of xanthate chain-transfer agent S-(2-cyano-2-propyl) O-ethyl xanthate 
The xanthate agent was synthesized according to a procedure reported in the literature.20 The 
purity of the xanthate was determined by 1H NMR spectroscopy and was 98 %. 
 
3.2.3 Synthesis of PVP macro-RAFT agent 
The starting PVP blocks were synthesized via RAFT-mediated polymerization using a xanthate 
RAFT agent. The polymerizations were carried out as follows: 
The xanthate RAFT agent (0.09 g, 5 x10-4 mol), NVP (10 g, 9 x 10-2 mol) and AIBN (0.017g, 
1.03 x 10-4 mol) were placed in a dry, pear-shaped 50 mL Schlenk flask and sealed using a 
rubber septum. The polymerization mixture was degassed via four freeze-pump-thaw cycles 
followed by introduction of ultra-high purity argon gas. The flask was immersed in an oil bath 
preheated at 60 °C. The polymerization reactions were stopped after 6 hours where the reaction 
mixture became very viscous and stirring was impaired. The polymerization mixture was diluted 
with dichloromethane (25 mL) and precipitate in diethyl ether (250 mL). The polymer was 
recovered by filtration and immediately dried under vacuum at ambient temperature. 
 
3.2.4 Synthesis of PVP-b-PVAc block copolymers  
For the synthesis of the diblock copolymers, the PVP macro-RAFT agent (starting block) was 
dissolved in methanol (2 mL) (a minimal amount of methanol was used in order to dissolve the 
PVP macro-RAFT agent in the hydrophobic VAc monomer). Vinyl acetate (7 g, 8.3 x 10-2 mol), 
AIBN (0.005 g, 3 x 10-5 mol) and the starting block (1 g) were placed in a Schlenk flask and  
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degassed via freeze-pump-thaw. The flask was immersed in an oil bath at 60 °C for 4 hours. The 
polymer was isolated by precipitation in diethyl ether and dried under vacuum at ambient 
temperature. 
 
3.2.5 Polymer characterization 
The block copolymers were characterized by 
1
H NMR spectroscopy using a 600 MHz 
spectrometer Varia Unity Inova instrument. Samples were dissolved in either deuterated dimethyl 
sulfoxide (DMSO-d6), deuterated chloroform (CDCl3) or deuterium oxide (D2O).  
 
The molecular weights were determined using size exclusion chromatography (SEC). The 
instrument setup consisted of a Shimadzu, LC-10AD pump, a column system fitted with a 50 x 8 
mm guard column in series with three 300x8 mm, 10 µm particle size GRAM columns (2 x 3000 
Å and 100 Å) obtained from PSS, a Waters 2487 dual wavelength UV detector and a Waters 
2414 differential refractive index (DRI) detector all in series. 100 µL injection volumes are 
sampled individually with the oven temperature of the column and DRI detector kept at 40 °C. 
The solvent, dimethylacetamide (DMAc) used was stabilized with 0.05 % BHT (w/v) and 0.03 
% LiCl (w/v). Polymer samples were filtered through 0.45 µm GHP filters prior to analysis. 
Calibration was done using poly(methyl methacrylate) PMMA standard sets (Polymer 
Laboratories) ranging from 690 to 1.2 x 106 g/mol.  
 
HPLC was performed using a Waters 2690 separations Module (Alliance), a dual pump setup 
comprising a Agilent 1100 series variable wavelength UV detector, and PL-ELS 1000 detector. 
Data was recorded and processed using PSS WinGPC unity (Build 2019) software. A C18-
grafted silica column was used (Luna RP C18 3 µm, 150 mm, 4.60 mm, Phenomenex) at 30 °C. 
The ELSD nebulizer temperature was 70 ⁰C. The flow rate was 0.5 mL min-1. For GPEC 
analysis, the mobile phase was acetonitrile/ deionized water (with 0.1 % formic acid) 65:35 
(v/v). Prior to HPLC and GPEC analyses, PVP-b-PVAc were dialysed for 24 h in distilled water 
using SnakeSkin® pleated dialysis tubing (Pierce, 3.5 KDa MWCO). Samples were prepared in 
the same solvent composition as the mobile phase at concentrations of 5 mg mL-1. The injection  
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volume was 20 µL. Homopolymers of PVP90 (Mn,NMR 8000 g.mol-1 (PMMA equivalents in 
DMAc, Đ = 1.3) and PVAc200 (Mn,SEC 18 000 g.mol-1 (PS equivalents in THF, Đ = 1.2) were 
prepared via xanthate-mediated polymerization and were used as a reference to estimate the 
elution volume of the PVP and PVAc homopolymers. Homopolymers and block copolymers 
were dissolved in 65:35 (v/v) acetonitrile/water. The gradient ranged from 65/35 
acetonitrile/water to 100 % acetonitrile. 
 
3.2.6 Self-assembly of PVP-b-PVAc block copolymers 
Self-assembly of the PVP-b-PVAc block copolymers was achieved by the dialysis method. A 
typical procedure is as follows: PVP-b-PVAc block copolymer (50 mg) was dissolved in DMSO 
(5 mL). The solution was stirred for 15 minutes at room temperature. The homogeneous solution 
was dialyzed against distilled deionized water for 24 hours using Snakeskin® dialysis tubing 
(MWCO 3500 g/mol dextran equivalents). The water was replaced every 6 hours. The polymer 
was recovered by freeze-drying for 24 hours. 
 
3.2.7 Determination of the critical micelle concentration (CMC) of PVP-b-PVAc block 
copolymers 
The CMC of the block copolymers were determined using pyrene as probe. The fluorescence 
excitation spectra of pyrene were measured at varying PVP-b-PVAc concentrations using a 
Perkin Elmer Luminescence LS50B spectrometer using FL Winlab version 4.0 for data 
processing. Aqueous solutions of PVP-b-PVAc of varying concentration (0.0001 – 1 mg/mL) 
were prepared. 15 µL of pyrene dissolved in acetone (1.8 x 10-4 M) was added to 4.5 mL of the 
PVP-b-PVAc aqueous solutions of varying concentration (pyrene concentration 6 x 10-7 M). The 
polymer solutions containing pyrene were left for 24 hours at room temperature in the dark to 
equilibrate the partitioning of pyrene into the hydrophobic domain of the polymer. The excitation 
spectra were recorded from 300 nm to 360 nm with the emission wavelength at 390 nm. The 
spectra were recorded with a scan rate of 250 nm min-1. The intensity ratio of I
338
/I
336 
was plotted 
against the logarithm of the PVP-b-PVAc concentration to determine the CMC. 
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3.2.8 Size distribution and morphology of PVP-b-PVAc block copolymers 
The particle size and particle size distribution of the PVP-b-PVAc block copolymers were 
determined by dynamic light scattering (DLS) using a Malvern Instrument ZetaSizer Nano ZS90 
equipped with a 4 mW He-Ne laser, operating at a wavelength of 633.0 nm. The scattered light 
was detected at a scattering angle of 90° at 25 °C or 37 °C. The final particle size and size 
distribution were obtained from three measurements, each comprising 10 – 15 sub-runs, and 
calculated via a CONTIN analysis.  
 
TEM of the PVP-b-PVAc samples were carried out in order to observe the morphology of the 
self-assembled PVP-b-PVAc block copolymers. TEM micrographs were obtained using a LEO 
912 microscope operating at an acceleration voltage of 120 kV. A drop of the sample solution 
was deposited onto a copper grid and dried at room temperature. The samples were negatively 
stained with uranyl acetate. 
 
3.2.9 Multiangle static light scattering (MASLS) 
Multiangle static light scattering (MASLS) measurements were performed to determine the 
radius of gyration of the PVP-b-PVAc block copolymers in water. Measurements were 
performed on an ALV 7002 Correlator, ALV-SP/86 goniometer, RFIB263KF Photo Multiplier 
Detector with ALV 200 µm Pinhole detection system and a Cobolt Samba-300 DPSS laser. The 
wavelength was set to 532 nm, power to 300 mW and the temperature was controlled by a Haake 
Phoenix II – C30P thermostatic bath. All measurements were carried out at 25 °C. Toluene was 
used as a calibration standard.  
 
Polymer solutions were prepared in Millipore water. All samples were passed through a 0.45 µm 
nylon filter prior to analysis. Then, samples were subjected to MASLS measurements using 6 
angles ranging from 50° to 120° in 10° increments for four polymer concentrations above the 
CMC (0.25 to 2 mg/mL). 
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The Rh was determined by DLS which is based on the Stokes-Einstein equation  
 
 =  
	
6  
 
in which kB is the Boltzmann constant, T is the absolute temperature, η is the solvent viscosity, 
and Γ is the decay rate. q is the scattering vector and given by the equation 
 
 =  4 sin

2 
 
with θ being the measurement angle, nm the refractive index of the solvent and λ the wavelength 
of the light in vacuum. 
The weight-averaged molecular weight (Mw), the radius of gyration (Rg) and second virial 
coefficient (A2) were calculated based on the equation 
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where R is the solute Rayleigh ratio expressed by the equation 
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Here Rtol,90 is the Rayleigh ratio of toluene at an angle of 90°, n is the refractive index of the 
solvent, I, Io and Itol are the scattering intensities of the solution, solvent, and toluene, 
respectively, and θ is the measurement angle.KR is the optical constant defined as 
 
 = 4
	
,-. 
	 //#!
	
 
 
 
 
Stellenbosch University http://scholar.sun.ac.za
Chapter 3 Synthesis, characterization and self-assembly of poly(vinylpyrrolidone)-b-poly(vinyl acetate) 
 
 
49 
where dn/dc is the refractive index increment and NA is Avogadro’s constant. The dn/dc was 
calculated for each polymer based on the composition of the block copolymer and the dn/dc of 
PVP and PVAc in water at 25 °C.21 
 
The data were analysed by the graphical method first reported by Zimm,22 which involves the 
extrapolation of the scattering data to both zero angle and zero concentration, simultaneously. 
This can be achieved by plotting KRc/Rq vs. q2 + (constant k)c, where k, an arbitrary 
mathematical constant with no physical significance is chosen to give a convenient spacing of 
the data points on the graph. The initial slope of the curve produced by points extrapolated to c = 
0 is proportional to Rg2, whereas the slope of the curve of points extrapolated to θ = 0 is 
proportional to A2 . Extrapolation of c = 0 and θ = 0 yields an intercept inversely proportional to 
Mw. However, due to the well-known problem of static light scattering analysis of block 
copolymers (which are polydisperse in composition and molecular weight) the quantities 
obtained by Zimm have to be treated only as apparent values. 
 
3.2.10 Stability of PVP-b-PVAc block copolymers in biological environment 
The stability of the block copolymers was assessed by DLS. The stability of the block 
copolymers was investigated in the systems mimicking biological fluids (PBS, pH 7.4) and PBS 
containing 20 % fetal calf serum (FCS). The PVP-b-PVAc samples were prepared as described 
in section 3.2.6. The solutions were incubated at 37 °C, and DLS measurements were recorded 
out at specific time intervals, at 37 °C.  
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3.3 Results and discussion  
3.3.1. Synthesis and characterization of PVP macro-RAFT-agent and PVP-b-PVAc block 
copolymers 
PVP macro-RAFT agent was successfully synthesized using S-(2-cyano-2-propyl) O-ethyl 
xanthate. From Table 3.1 it is seen that the number average molecular weight (Mn) of the 
homopolymerizations obtained by 1H NMR and SEC were closely in agreement to the theoretical 
Mn.  
 
 
 
 
 
 
a
conversion 
bMn,SEC based on PMMA standards  
cMn,NMR determined as the ratio of the xanthate signal to monomer backbone signal 
 
A typical 1H NMR spectrum of the PVP macro-RAFT agent is shown in Figure 3.1. Peak 
assignments are indicated in Figure 3.1 and were made based on the expected structure. The 
peaks marked with an asteriks are diethyl ether. The signal at 4.60 ppm from the omega chain 
end and the polymer peaks between 4.0-3.5 ppm was used to calculate the number average 
molecular weight (Mn) of the PVP macro-RAFT agent.  
 
 
 
 
 
 
 
 
 
 
 
Polymer    αa 
(%) 
Reaction 
time (hr) 
Reaction  
temperature 
Mn,theo, 
(g/mol) 
Mn,SECb 
(g/mol) 
Mn,NMRc 
(g/mol) 
Đ 
PVP macro-
RAFT 
60 6 60 °C 10 000 6500 9500 1.3 
Table 3.1: Polymerization conditions, conversion and molecular weight of PVP macro-RAFT-agent 
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In a second step VAc is added to the PVP-macro RAFT agent (starting hydrophilic block) to 
obtain the corresponding PVP-b-PVAc block copolymer. The incorporation of the VAc units 
into the PVP macro-RAFT agent was evidenced by 1H NMR spectroscopy. A typical 1H NMR 
spectrum of PVP-b-PVAc is shown in Figure 3.2. Peak assignments are indicated in Figure 3.2 
and were made based on the expected structure. The signals at 3 – 4 ppm are assigned to the 
monomer repeat units of PVP (a, e). The signal at 4.9 ppm is attributed to the methine peak of 
PVAc (g) 
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Figure 3.1: 1H NMR spectrum of PVP macro-RAFT agent in CDCl3  
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The various block copolymers of fixed hydrophilic PVP block length and varying hydrophobic 
PVAc block length are tabulated in Table 3.2. It must be mentioned that SEC data is likely not to 
reflect the true molar masses of the block copolymers due to the calibration based on PMMA 
standards. Furthermore, SEC analysis of block copolymers suffers inherent difficulties 
particularly when the blocks have a strongly differing polarity and interaction with the solvent 
and the column. This could perhaps explain the high Mn values obtained from SEC. 
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Figure 3.2: 1H NMR spectrum of PVP-b-PVAc in CDCl3  
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Table 3.2: Synthesis of PVP and PVP-b-PVAc block copolymers with different PVAc block length 
 
 
 
 
 
 
 
 
aNumber average molecular weight of vinyl acetate block based on initial molar ratios of the polymerization mixture 
and conversion 
bMn,SEC based on PMMA standards  
 
Figure 3.3 shows the SEC chromatogram for the chain extension of PVP-macro RAFT agent to 
vinyl acetate. An obvious peak shift of the PVP macro-RAFT to PVP-b-PVAc (i.e. low 
molecular weight to higher molecular weight) was seen. This indicated that propagation started 
from the initial xanthate end-functional PVP, and generated the PVP-b-PVAc diblock 
copolymer. The small tail seen at high elution time (i.e. low molecular weight) in the PVP-b-
PVAc SEC chromatogram is ascribed to PVP homopolymer. These chains are dead or inactive 
chains that are unable to reinitiate in the second step. In the chain extension step, propagating 
chains are initiated either by primary radicals that originate from the azo-initiator (in this case 
AIBN) or by radicals from the leaving group of the RAFT agent. The polymeric radicals 
terminate by either reacting with the RAFT agent or with the same initiating group (initiator or 
leaving group of RAFT agent). Therefore, numerous different structures exist in these systems 
which could contribute towards the high Mn and dispersity (Đ) obtained. Indeed, the chains that 
contain the active RAFT agent are highly preferable since they can possibly be chain extended 
upon addition of PVAc monomer, resulting in block copolymer formation. Inherent to the 
mechanism of RAFT polymerization, PVAc homopolymer is inevitably formed.  
 
 
 
 
Polymer Experimental 
description 
Mn,theo,a 
(g/mol) 
Theoretical 
(co)polymer 
composition 
Mn,SECb 
(g/mol) 
Đ 
1 PVP90-xanthate-mediated 
diblock copolymerization of 
VAc 
18000 PVP90-b-PVAc210 64100 1.6 
2 PVP90-xanthate-mediated 
diblock copolymerization of 
VAc 
22016 PVP90-b-PVAc256 74800 1.6 
3 PVP90-xanthate-mediated 
diblock copolymerization of 
VAc 
24900 PVP90-b-PVAc290 91000 1.7 
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The purification of the block copolymers is important for their application as drug delivery 
carriers (Chapter 4). The dialysis method was implemented to purify the block copolymers. This 
method allows for low molecular weight contaminants (e.g. solvent, residual monomer and 
homopolymer) to be removed by diffusing through a dialysis membrane of a specific molecular 
weight cut-off (MWCO). The purification of the PVP-b-PVAc block copolymer via the dialysis 
method proved to be a very efficient purification technique. This is indicated in the 1H NMR 
spectra (Figure 3.4) where unpurified and purified PVP-b-PVAc block polymers are compared. 
Impurities are indicated by the arrows in the spectra. 
 
 
 
 
 
 
 
 
 
Figure3.3: Normalized SEC chromatograms for the chain extension of starting homopolymer chain-
transfer agent (PVP macro-RAFT) with vinyl acetate  
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3.3.2 Gradient HPLC characterization of PVP-b-PVAc block copolymers 
Previously in our group, Pound et al.23 successfully separated double hydrophilic block 
copolymers of PEG-b-PVP and amphiphilic block copolymers of PEG-b-PVAc using gradient 
HPLC, also referred to Gradient Polymer Elution Chromatography (GPEC). In our study, the 
amphiphilic block copolymers of PVP-b-PVAc were therefore separated using the same method 
and conditions already developed. Acetonitrile and water were chosen as the eluent mixture 
which was able to dissolve all homo- and block copolymers. A dual detector system was used 
(ELSD detector to identify the macromolecular species and UV detection for the xanthate 
functionality). Homopolymers and block copolymers were dissolved in a 65/35 (v/v) 
ACN/water. Homopolymers of PVP90 and PVAc200 and block copolymers (PVP90-b-PVAc210 
and PVP90-b-PVAc290) were separated using GPEC with a gradient with increasing acetonitrile 
content. By increasing the hydrophobicity of the mobile phase, PVP-b-PVAc block copolymers 
eluted first follwed by PVAc homopolymer. 
 
 
 
8 6 4 2 0
ppm
a 
b 
Figure 3.4: 1H NMR spectra of a) PVP-b-PVAc in CDCl3 not dialyzed (unpurified) b) PVP-b-
PVAc in CDCl3 dialyzed (purified) 
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Figure 3.5: Gradient polymer elution chromatogram of a) PVP90 prepared in bulk in the presence of 
S-2-(cyano-2-propyl) )-(O-ethyl xanthate) b) PVAc200 prepared in bulk in the presence of S-(2-
ethylpropionate)-(O-ethyl xanthate)) c) PVP90-b-PVAc290 (-), PVP90-b-PVAc210 (- -)block copolymers  
Figure 3.5 shows the chromatograms of the homopolymers (Figure 3.5 (a) and (b)) and of PVP-
b-PVAc with different PVAc length (Figure 3.5 (c), PVP90-b-PVAc290 and PVP90-b-PVAc210). 
The PVP90-b-PVAc210 and PVP90-b-PVAc290 block copolymers present a broad peak with a 
bimodal distribution (shoulder), eluting earlier than PVAc, as expected. The shoulder could 
indicate the presence of PVAc homopolymer. PVP90-b-PVAc210 eluted slightly earlier than 
PVP90-b-PVAc290 due to the shorter PVAc block length. No trace of PVP homopolymer was 
detected (the presence of any short PVP chains was removed by dialysis). The chromatograms 
also show a slight overlap of the PVP-b-PVAc with PVAc homopolymer. This could indicate 
that most of the VAc was polymerized from the PVP starting block and that a small fraction of 
the block copolymer also consists of PVAc homopolymer. This is not unexpected, and in 
agreement with the theory for RAFT polymerization. 
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An additional experiment was carried out whereby PVP90, PVAc200 and PVP90-b-PVAc290 were 
mixed together (ratio 1:1:1) in 65/35 (v/v) ACN/water. Figure 3.6 (a) shows the separation of the 
mixture of homopolymers and the block copolymers. As expected, PVP90 eluted first folowed by 
PVP90-b-PVAc256 and PVAc200. Figure 3.6 (b) represents the chromatogram of only the PVP90-b-
PVAc290 and PVP90-b-PVAc210 and confirms that the main structure was block copolymer. 
 
 
 
 
 
 
 
 
 
 
 
 
Based on the GPEC measurements it is difficult to get quantitative information regarding the 
presence of PVAc homopolymer contamination in the block copolymers. Further optimization 
including different mobile and stationary phases for this separation is recommended as future 
work. 
 
3.3.3 Self-assembly behavior of PVP-b-PVAc block copolymers 
1H NMR spectroscopy is a convenient characterization method to obtain a first indication of the 
self-assembly process of amphiphilic block copolymers in various solvents.24 A comparison of 
the 1H NMR spectra of PVP-b-PVAc in deuterated water (selective solvent for the PVP block) 
and in deuterated chloroform (a common solvent for both blocks) allows for the identification of 
the formation of aggregates.  
Figure 3.7 (a and b) represents the 1H NMR spectra of PVP-b-PVAc in CDCl3 and PVP-b-PVAc 
in D2O. Figure 3.7 (a) shows the 1H NMR spectrum of PVP-b-PVAc in CDCl3. Self-assembly of 
PVP-b-PVAc is not expected in CDCl3 and all peaks of the hydrophilic PVP (3 – 4 ppm) and 
hydrophobic PVAc (2 – 2.1 ppm) were detected. The self-assembly of PVP-b-PVAc into either  
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Figure 3.6: Gradient polymer elution chromatogram of a) mixture of PVP90, PVAc200 and PVP-b-
PVAc290 b) PVP-b-PVAc290 (-) and PVP-b-PVAc210 (- -) of varying PVAc block length 
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micelles or vesicles was confirmed by 1H NMR in D2O. The predominant peak is that of the PVP 
(protons from the repeat units of polymer backbone, 3 – 4 ppm) - the corona of the micelle- or 
vesicle-like structure - while the peaks of PVAc are suppressed (2 – 2.1 ppm) and not visible (5 
ppm) due to the limited mobility of the PVAc-chains in the hydrophobic core or bilayer. 
1H NMR spectroscopy confirmed that the PVP-b-PVAc block copolymers have the ability to 
self-assemble in aqueous media. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.4 CMC of PVP-b-PVAc block copolymers 
The thermodynamic stability of the block copolymer micelle upon dilution is an important factor 
for in vivo application. This is indicated by the CMC of the block copolymer. One of the 
requirements of a drug delivery carrier is its stability to be maintained at a very high dilution. 
This is crucial and therefore a low CMC is essential. 
 
 
 
Figure 3.7: 1H NMR spectra of a) PVP90-b-PVAc290 in CDCl3 b) PVP-b-PVAc in D2O 
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Several methods can be used to determine the CMC of amphiphilic block polymers. These 
include surface tension,25 dye solubilisation,26,27 light scattering and fluorescence spectroscopy.28 
The use of fluorescent probes, such a pyrene is the most common and accurate method used to 
determine the CMC.29 Pyrene is a highly hydrophobic aromatic hydrocarbon and sensitive to the 
polarity of the surrounding environment. The self-aggregation behavior of PVP-b-PVAc block 
copolymers in aqueous environment were studied using pyrene as a fluorescent probe. The 
transfer of pyrene from a hydrophilic to a more hydrophobic environment results in a red shift in 
the excitation spectrum.30,31 
 
 
 
The excitation spectra of pyrene is shown in Figure 3.8. A small change in the spectra is seen for 
the polymeric solutions for which the copolymer concentration is lower than the CMC. When the 
concentration increased above the CMC, an increase in the intensity and a red shift is seen. The 
CMC of the copolymers was calculated by the crossover point of the intensity ratio of I338 nm/I336 
nm from the pyrene excitation spectra versus the logarithm of the concentration for the various 
PVP-b-PVAc copolymer solutions (Figure 3.9). The ratio I338 nm/I336 nm is almost constant at low 
polymer concentrations, but from a certain concentration, it starts to increase steadily, indicative 
of the incorporation of pyrene into the hydrophobic region of the vesicles. The CMC for PVP90-
b-PVAc290, PVP90-b-PVAc256 and PVP90-b-PVAc210 were 0.0012 mg/mL, 0.0014 mg/mL and 
0.0085 mg/mL, respectively, which is in agreement with the copolymer composition. 
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Figure 3.8: Fluorescence excitation spectra of pyrene (6.0 × 10 –7 M) containing PVP90-b-PVAc290 at 
different concentrations (0.0001 – 1 mg/mL) 
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An increase in the hydrophobic block length serves to lower the CMC.32 The results indicate that 
an increase in the molecular weight of the hydrophobic block decreases the CMC or, 
alternatively, the CMC of the block copolymer decreased with increasing PVAc block length, as 
expected. This indicates that the hydrophobic block length plays a critical role in the formation 
and the CMC of the polymer vesicles. Such extremely low CMC values obtained is an important 
factor for the structural stability of the PVP-b-PVAc block copolymers, which is necessary for 
long circulating polymer drug carriers in the body.33  
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Fluorescence intensity ratio I338/I336 for pyrene as a function of logarithm of concentration 
for PVP90-b-PVAc290. The CMC was calculated from the intersection of the horizontal line at low 
polymer concentration and the tangent of the curve at high polymer concentration 
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Polymer Particle size (Zave (nm)) 
DLS 
     PDI Particle size (nm) 
TEM 
PVP90-b-PVAc210 190 ± 1.8 0.09 120 – 150 nm 
PVP90-b-PVAc256 180 ± 4.2 0.05 120 – 150 nm 
PVP90-b-PVAc290 200 ± 3.5 0.05 90 – 200 nm 
3.3.5 Size distribution and morphology of PVP-b-PVAc 
Measurements were carried out by DLS, TEM and SLS to further evaluate the properties of the 
block copolymers in terms of the particle size, the particle size distribution and the morphology. 
The results are tabulated in Table 3.3. 
 
Table 3.3: Particle size of PVP-b-PVAc block copolymers of varying PVAc block length determined by 
DLS and TEM 
As mentioned earlier, the self-assembly of the PVP-b-PVAc block copolymers was carried out 
via the dialysis method. Here, the block copolymer is dissolved in a solvent (DMSO) followed 
by dialysis in which the water gradually replaces the solvent, which induces the self-assembly of 
the block copolymer. The particle size (diameter) of the self-assembled PVP-b-PVAc block 
copolymers in water was 180 – 200 nm with a monomodal size distribution as seen in Figure 
3.10. No significant variation in particle size was seen for the various PVP-b-PVAc block 
copolymers of varying PVAc block length. The low polydispersity (< 0.1) strongly suggests the 
formation of monodisperse particles, which is usually the case for spherical micelles and also 
possible for vesicles. Note that DLS provides the hydrodynamic radius of the particles, at this 
stage no conclusion about the shape or morphology of the self-assembled PVP-b-PVAc block 
copolymers can be made.  
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It has been reported in literature that the size of the particles is dependent on the polymer 
concentration. For example, Zhang and coworkers found that vesicles are preferentially formed 
at higher polymer concentrations compared to concentrations at which micelles are formed.34 
This is likely attributed to the higher probability of interpolymer aggregation at higher polymer 
concentration. The effect of different initial concentration of the PVP-b-PVc block copolymer 
(10 mg/mL – 1 mg/mL) on the particle size was investigated. In our case, it was found that the 
particle size of the self-assembled PVP-b-PVAc remained between 160 – 200 nm at various 
polymer concentrations (data not shown). 
In another study, Vangeyte et al.35 investigated the influence of various preparation techniques 
and solvents used, on the particle size of poly(ethylene oxide)-b-poly(ε-caprolactone) (PEO-b-
PCL) in water. The three preparation methods studied were the dialysis of the polymers in a 
common organic solvent against water, rapid addition of water to the polymer organic solutions, 
and rapid addition of the polymer organic solutions into water. Results indicated that direct 
dialysis of the copolymer solutions in an organic solvent against water resulted in large and 
polydisperse particles (> 1 µm). On the other hand, the two other methods that consist of the 
rapid addition of the organic solution to water and vice versa resulted in well-defined, 
monodisperse particles (30 – 60 nm). However, the particle size was dependent on the organic 
Figure 3.10: DLS size distributions of PVP-b-PVAc of varying PVAc block length 
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solvent used. The research group of Eisenberg also reported on the relationship between the 
morphology of poly(styrene)-b-(poly(acrylic acid) (PS-b-PAA) block copolymers and the nature  
of the common solvent. It was found that the block copolymers yield only spherical micelle-like 
aggregates in DMF, while vesicles were obtained in THF.36 
 
In the present study, the effect of the preparation method and solvent on the self-assembly of the 
PVP-b-PVAc block copolymers was not investigated. Self-assembly studies were only carried 
out via the dialysis method using only DMSO as organic solvent. Importantly, the self-assembly 
of PVP-b-PVAc block copolymers via the dialysis method was reproducible. 
 
The morphology of the PVP-b-PVAc in water (5 mg/mL) was visualized by TEM. The self-
assembled PVP-b-PVAc block copolymers were clearly distinguished as uniform, spherical 
structures as shown in Figure 3.11. Interestingly, we observed the characteristic feature for 
vesicle structures: a dark corona surrounding a light core. Eisenberg and Dischner6 demonstrated 
the influence of the fraction of the hydrophilic block and the hydrophobic block on the molecular 
shape of the copolymer and particle morphology. The present observation is in line with their 
findings. Since the hydrophobic PVAc block is the dominant segment in the PVP-b-PVAc block 
copolymer, the formation of vesicles and bilayers is likely to be expected. The particle sizes 
obtained by TEM ranged from 150 – 200 nm with a few slightly smaller particles of 100 nm. The 
particle diameter derived from TEM was slightly smaller than that measured and compared to 
DLS. This is attributed to the dehydration and shrinkage of the particles during TEM sample 
preparation (drying process), as reported in previous studies.37 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.11: TEM image of PVP90-b-PVAc290 block copolymer. Black corresponds to hydrophobic 
region (bilayer) and grey to hydrophilic regions. The insert is a schematic representation of the self-
assembled, vesicular-like structure of the PVP-b-PVAc  
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In addition to DLS and TEM, SLS experiments were performed in water to confirm the structure 
of the PVP-b-PVAc block copolymers. From scattered light intensity measurements at various 
PVP-b-PVAc concentrations, we could determine the radii of gyration (Rg) and the weight 
average molecular weight (Mw) of the block copolymer aggregates. A typical Zimm plot of the 
scattering intensity versus the square of the scattering vector (including the extrapolation to zero 
concentration and zero angle) is given in Figure 3.12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The ratio Rg/Rh is a characteristic value that depends on the morphology of the aggregates 
formed. From the Rg and Rh values obtained by DLS and SLS, we calculated the Rg/Rh ratio, 
which provided information on the structure of the PVP-b-PVAc in water. Table 3.4 summarizes 
the results obtained by combining DLS and SLS analysis for PVP90-b-PVAc290 and PVP90-b-
PVAc210. 
 
 
 
 
 
Figure 3.12: Zimm plot for PVP90-b-PVAc210 extrapolated to zero angle and zero concentration in 
water at 25 °C. Squares represent experimental data, measurements at four different 
concentrations, from 50° – 120°. Circles represent simulated data 
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Table 3.4: Physicochemical parameters of PVP-b-PVAc block copolymers obtained by SLS and DLS 
PVP-b-PVAc Rha 
(nm) 
Rgb 
(nm) 
Rg/Rh Mw(particle)c 
(g.mol-1) 
ρ
d 
(g/cm3) 
Nagge S/Naggf 
(nm2) 
PVP90-b-PVAc290 105 119 (± 3.5) 1.15 1.1 x108 0.3 1200 
 
52 
PVP90-b-PVAc210 96 98.7 (± 5.1) 1.02 6.3 x 107 0.1 1000 62 
aHydrodynamic radius (Zave/2) determined by DLS. bRadius of gyration, extrapolated to zero 
concentration. cMw(particle) weight average molecular weight of particles determined by SLS. dρ is the 
density of the particles calculated by ρ = Mw(particle)/NAV, V is based on Rh.  eAggregation number was 
calculated by using the weight average molecular weight determined by SLS and number average 
molecular weight determined by SEC. f Surface area per PVP chain  
 
The hydrodynamic radius (Rh) was determined by DLS before the SLS measurements were 
started. DLS measurements give a Rh in the range of 95 – 100 nm for both PVP90-b-PVAc290.and 
PVP90-b-PVAc210. Theoretical values for the Rg/Rh ratio are 0.78 for hard spheres, 1 for vesicles 
with a thin membrane, and values greater than 1.5 are for elongated structures or polymers with 
extended conformations (e.g. rod-like micelles).6,38,39 For the reported block copolymers, the 
ratios of Rg/Rh from light scattering (Table 3.4) correspond well to the theoretical value for 
vesicles (~1). The results indicate that the PVP-b-PVAc block copolymers self-assembled 
predominantly into vesicular structures, which is consistent with the TEM images which show 
spherical bilayer structures. The density of the self-assembled structures were also calculated and 
found to be 0.3 g/cm3 and 0.1 g/cm3 for PVP90-b-PVAc290 and PVP90-b-PVAc210. These values 
are reasonable for water-swollen yet solid polymer self-assembled structures. The aggregation 
number (Nagg) was calculated to be 1200 and 1000 for PVP90-b-PVAc290 and PVP90-b-PVAc210, 
respectively. These values are typical in the range for vesicles. As expected, the aggregation 
number increased with increasing hydrophobic PVAc block length and molecular weight.  
 
It is necessary to point out that variables such as the preparation method, the nature and 
composition of the solvent mixture, the water content, the relative hydrophilic/hydrophobic 
block length and the molecular weight of the block copolymer, all provide control over the 
resulting particle size, the aggregation number and morphology of self-assembled block 
copolymers.8,40-43 Therefore, depending on the type of system and conditions used, an entire 
range of morphologies can be obtained and only subtle changes in these variables can lead to  
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dramatic alterations in the physicochemical properties and morphologies of the self-assembled 
block copolymers. 
 
Based on the DLS, TEM and SLS results, PVP-b-PVAc block copolymers self-assembled into 
spherical, vesicle structures of 180 – 200 nm in diameter. For the application of PVP-b-PVAc 
block copolymers as drug carrier, these particle sizes obtained are suitable for passive targeting 
via the EPR effect. 
 
3.3.6 Stability of PVP-b-PVAc vesicles under physiological conditions 
Upon intravenous administration, polymer drug carriers encounter blood cells and plasma 
proteins before reaching the target cells. Serum is a complex fluid that is made up of serum 
albumin, lipoproteins immuno- , γ- and macroglobulins. Serum proteins can bind to or penetrate 
in the drug carriers which can result in changes in their physicochemical properties such as the 
particle size.44-46 The stability of PVP-b-PVAc was therefore investigated in physiological 
conditions (PBS, pH 7.4, 37 °C). Furthermore, in vitro studies are usually performed in the 
presence of serum (10 – 20 % FCS) (Chapter 5, Section 5.2.3). For this reason, the particle size 
stability of the PVP-b-PVAc carrier was also evaluated in PBS containing 20 % serum.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Stability of PVP90-b-PVAc290 (left) and PVP-b-PVAc210 (right) at 37 °C in PBS (pH 
7.5) and PBS/FCS as determined by DLS  
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Figure 3.13 shows the particle size stability of the PVP-b-PVAc block copolymers (0.5 mg/mL) 
incubated with PBS (pH 7.4, 37 °C) or PBS conatining 20 % serum. Prior to incubation studies 
in serum, a control experiment was carried out. As reported previously in the literature, DLS of 
biological fluids such as serum result in significant background signal (~ 60 nm) due to their 
heterogeneous nature.47 As a control experiment, the background scattering of PBS/FCS (20 % 
serum) was measured alone and considered insignificant. PVP90-b-PVAc290 and PVP90-b-
PVAc210 samples incubated in PBS were stable for more than 18 hours. For the PVP90-b-
PVAc290 block copolymer incubated in the prescence of serum, the particle size remained 
constant over 16 hours. PVP90-b-PVAc210 also showed stability over 18 hours in serum. The size 
stability of the vesicles is likely due to the PVP hydrophilic surface, which protects them from 
surface adsorption of serum components. High surface coverage of hydrophilic polymer chains is 
a favorable property for a drug carrier. This allows for prolonged blood circulation and 
protection of the carrier from protein adsorption.  
 
3.4 Conclusion 
PVP-b-PVAc block copolymers of constant hydrophilic PVP block length and varying 
hydrophobic block length were synthesized via a CRP technique. The ability of the block 
copolymers to self-assemble in aqueous solution was confirmed by 1H NMR, fluorescence 
spectroscopy, DLS, SLS and TEM. PVP-b-PVAc self-assembled into spherical vesicle-like 
structures ranging from 180 – 200 nm in aqueous solution. The low CMC values of the block 
copolymers should further allow for the PVP-b-PVAc carrier to maintain its vesicular 
morphology upon dilution. Furthermore, the stability of the PVP-b-PVAc carrier was maintained 
under physiological conditions in the presence and absence of serum. With these above 
mentioned properties, the PVP-b-PVAc block copolymer should be a versatile carrier for various 
hydrophobic and hydrophilic drugs. 
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Chapter 4  
Poly(vinylpyrrolidone)-b-poly(vinyl acetate): A potential drug carrier 
 
Abstract 
Poly((N-vinylpyrrolidone)-b-poly(vinyl acetate)) (PVP-b-PVAc) block copolymers of varying 
molecular weight and hydrophobic block lengths were synthesized via controlled radical 
polymerization and investigated as carriers for the solubilization of highly hydrophobic 
riminophenazine compounds. These compounds have recently been shown to exhibit a strong 
activity against a variety of cancer types. PVP-b-PVAc self-assembles into polymer vesicles in 
aqueous media, and the dialysis method was used to load the water-insoluble drug (clofazimine) 
into these polymer vesicles. The polymer vesicles were characterized by 1H NMR spectroscopy 
to confirm vesicle formation and the incorporation of the anti-cancer drugs into the polymer 
vesicles. Dynamic light scattering was used to determine the particle size and particle size 
distribution of the drug-loaded vesicles as well as the stability of the vesicles under physiological 
conditions. The size of the polymer vesicles did not increase upon loading with clofazimine, and 
the particle size of 180 – 200 nm and the narrow particle size distribution were maintained. The 
morphology of the vesicles was examined by transmission electron microscopy. The drug 
loading capacity and the encapsulation efficiency of the polymer vesicles were determined by 
UV/Vis spectroscopy. The polymer vesicles had a relatively high drug loading capacity of 20    
wt %. The results indicate that the present PVP-b-PVAc block copolymer could be a potential 
candidate as a drug carrier for hydrophobic drugs. 
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4.1 Introduction 
To date, various drug delivery and drug targeting systems have been developed or are currently 
under development for poorly water-soluble drugs. Many of the existing potent therapeutic 
agents such as anti-cancer drugs are restricted to being used intravenously due to their poor water 
solubility.1 Currently, conventional solubilizing agents (e.g. Cremophor EL®/ethanol) are used 
for the formulation in order to improve the solubility. However, these solubilizing agents have 
undesirable toxic side-effects such as hypersensitivity, neurotoxicity and nephrotoxicity.2,3 
Research focuses on the development of formulations that avoid the use of Cremophor EL® to 
allow an improved control of the toxicity and the pharmacological interactions caused by these 
anti-cancer agents. As an alternative approach for the solubilization of poorly water-soluble drug 
molecules, the use of amphiphilic block copolymers is currently the focus of interest in 
nanopharmaceuticals.4 
 
Polymer micelles used in drug delivery are formed from amphiphilic block copolymers 
consisting of a hydrophilic and a hydrophobic biodegradable and/or biocompatible polymer 
chain. In aqueous medium, amphiphilic block copolymers self-assemble into distinct structures 
comprised of a hydrophilic outer shell and a hydrophobic inner core. The hydrophobicity of the 
micellar core provides a host for the incorporation and solubilization of anti-cancer agents, which 
are mostly hydrophobic.5 The hydrophilic shell stabilizes the micelle structure and protects it 
from biological surroundings. Consequently, both the hydrophilic corona and the hydrophobic 
core of the micelle carriers control the physicochemical and biological properties of the drug 
delivery system. On the other hand, amphiphilic block copolymers, if made with suitable 
amphiphilic proportions, can also self-assemble into vesicular structures. In this case, the 
hydrophobic blocks self-assemble into bilayer structure whereas the hydrophilic block faces the 
inner and outer aqueous phases. The hydrophobic bilayer membrane can incorporate 
hydrophobic drugs while the hydrophilic core can incorporate hydrophilic drugs.  
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Polymer micelles and vesicles have emerged as versatile drug carriers during the past decades 
because of their attractive properties.6-8 As drug vehicles, they present numerous advantages, 
such as the reduction of side effects of anti-cancer drugs, minimization of drug degradation and 
of loss upon administration, prevention of harmful or undesirable side-effects, and enhancement 
of the drug bioavailability. In addition, their nanoscale size (10 – 200 nm in diameter) prevents 
them from uptake by the reticulo-endothelial system (RES) and allows for higher accumulation 
at the target site through the enhanced permeation and retention (EPR) effect. 9,10 The 
biocompatible hydrophilic corona provides these micelles or vesicles with “stealth” properties. 
The low critical micelle concentration (CMC) makes them relatively stable, prevents them from 
rapid dissociation, and further allows for the drug to be retained over a longer period of time in 
the blood stream. This is crucial for the in vitro and in vivo application of polymer drug carriers. 
 
Clofazimine [3–(4–chloroanilino)–10–(4–chlorophenyl)–2,10–dihydro–2 (isopropylimino) 
phenazine] is a riminophenazine compound with anti-mycobacterial and anti-inflammatory 
activity (Figure 4.1).11 It is one of the most active antimycobacterial agents in this class of 
compounds (the riminophenazines). In 1957, Barry et al.12 investigated the antituberculosis 
activity of clofazimine. To date, clofazimine has primarily been used in the treatment of 
mycobacterial diseases such as leprosy and drug-resistant tuberculosis. It has also been used in 
the treatment of Mycobacterium avium infections in AIDS patients.13 Recently clofazimine has 
also been reported to inhibit the growth of various cancer cell types.14,15 
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Figure 4.1: Chemical structure of parent compound clofazimine and its derivatives 
(riminophenazines) R1 and R2 are chlorine substituted rings 
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Like many anti-cancer drugs, clofazimine is a highly hydrophobic drug (water-solubility below 
0.225 mg/L (virtually insoluble)), which limits its potential therapeutic value. O’Reilly et al.16 
investigated systems of sodium cholate and sodium cholate/fatty acid mixtures to improve the 
solubility of clofazimine. A 60-fold increase of clofazimine solubility was observed. Attempts of 
modifying the chemical structure of clofazimine have been proven to be unsuccessful.17 To 
enhance the solubility and bioavailability of clofazimine, the use of cyclodextrins, which are 
water-soluble cyclic oligosaccharides composed of glucose units, has been reported by Salem et 
al.17 The modified cyclodextrin could be used to solubilise riminophenazines. The solubility of 
clofazimine increased by about 4000-fold. Hernandez-Valdepena and coworkers recently, 
synthesized nanoaggregates formed by randomly hydrophobised polyacids derived from 
poly(methyl vinyl ether-alt-maleic acid) (PMVEMAc), which were able to solubilize 
clofazimine in neutral aqueous media.18 The encapsulation of clofazimine into liposomes has 
also been reported to solubilise the drug and furthermore improve the overall therapeutic 
efficacy. Mehta et al.19 showed that clofazimine can be effectively encapsulated in liposomes 
with an efficiency of 95 to 100 %. In vitro and in vivo studies have demonstrated that liposome-
encapsulated clofazimine is much less toxic than free clofazimine. This is advantageous as the 
encapsulated drug could be administered at higher doses than free drug due to the water-
insolubility of the drug. 
In this study, PVP-b-PVAc block copolymers were evaluated as possible carriers for the 
hydrophobic drug, clofazimine. Drug-loaded vesicles were prepared via physical encapsulation 
as illustrated in Figure 4.2. The drug-loaded vesicles were characterized for drug loading 
efficiency, morphology and stability as potential carriers for hydrophobic drugs.  
 
 
 
 
 
 
 
 
  
PVP-b-PVAc block copolymer 
Clofazimine-loaded PVP-b-PVAc vesicles 
Clofazimine 
(anticancer drug) 
 
Figure 4.2 Schematic representation of the encapsulation of clofazimine into PVP-b-PVAc  
polymer vesicles 
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4.2. Materials and methods 
4.2.1 Chemicals 
Dimethyl sulfoxide (Merck, 99 %) was used as received, clofazimine (B663) was obtained from 
the University of Pretoria. Dulbecco’s modification of Eagles Medium (DMEM) (sterile) was 
purchased from Sigma Aldrich. Distilled deionized water was obtained using a Millipore Milli-Q 
purification system and used in all the experiments. Fetal calf serum (FCS) (sterile) and 
phosphate buffer saline (PBS) (pH 7.5, sterile) were purchased from Sigma-Aldrich. Block 
copolymers of PVP-b-PVAc were synthesized as described in Chapter 3. 
 
4.2.2 Loading of clofazimine into PVP-b-PVAc block copolymers 
Clofazimine was incorporated into PVP-b-PVAc block copolymers via the dialysis method. A 
typical procedure for the preparation of the drug-loaded vesicles is as follows. PVP-b-PVAc (50 
mg), and the hydrophobic drug, clofazimine (10 mg) were dissolved in DMSO (5 mL). The 
solution was stirred for 10 minutes at room temperature. The homogeneous solution was 
dialyzed against distilled water for 24 hours using a dialysis membrane (MWCO 3500 g/mol). 
The water was replaced every 6 hours. The resultant solution was lyophilized to obtain dry drug-
loaded PVP-b-PVAc samples for long-term storage. 
 
4.2.3 1H NMR measurements of block copolymers 
1H NMR measurements were performed on PVP-b-PVAc block copolymers. The 
1
H NMR 
spectra were recorded on a Varian 600 MHz Inova spectrometer (Varian Associates Inc. NMR 
Instruments). The self-assembly of the block copolymers and drug incorporation were confirmed 
using 1H NMR spectra in DMSO-d6 and in D2O. 
 
4.2.4 Size distribution and morphology of clofazimine-loaded PVP-b-PVAc 
The size and size distribution of the loaded and unloaded vesicles were determined by DLS using 
a Malvern ZetaSizer Nano instrument (ZS90) fixed at an angle of 90 degrees, equipped with a 4 
mW He-Ne laser operating at a wavelength of 633 nm. Time correlation functions were analysed 
using the CONTIN analysis software provided by Malvern, to obtain the hydrodynamic diameter 
of the particles (Zave) and the particle size distribution. TEM of the drug-loaded and unloaded 
PVP-b-PVAc samples were carried out in order to observe the morphology of the vesicles. TEM 
Stellenbosch University http://scholar.sun.ac.za
Chapter 4 Poly(vinylpyrrolidone)-b-poly(vinyl acetate): A potential drug carrier 
 
 76 
micrographs were obtained using a LEO 912 microscope operating at an acceleration voltage of 
120 kV. A drop of the sample solution was deposited onto a copper grid and dried at room 
temperature. The sample solution was negatively stained with uranyl acetate. 
 
4.2.5 Evaluation of the drug loading capacity and encapsulation efficiency of clofazimine-loaded 
PVP-b-PVAc  
The drug loading capacity and the encapsulation efficiency of clofazimine-loaded PVP-b-PVAc 
of different vesicle formulations were determined spectrophotometrically. A Perkin Elmer 
Lambda 20 photodiode array spectrophotometer was used to measure the UV-Vis spectra. It 
consisted of a holographic monochromator, pre-aligned deuterium and halogen lamps and a 
photodiode array detector. UV Winlab (version 2.0) software was used for data acquisition and 
processing. 
The drug encapsulation efficiency is defined as the ratio of the weight of the drug encapsulated 
in the vesicles to the weight of the drug initially used, while the drug loading content is the 
weight ratio of the drug encapsulated in the vesicles to that of the weight of the polymer vesicles. 
The loading capacity and the encapsulation efficiency are calculated using the following 
equations: 
Drug loading capacity (DLC) % = mass of drug in vesicles
mass of polymer vesicles
 x 100%  
Drug encapsulation efficiency (EE) % = mass of drug in vesicles
mass of drug initially used
 x 100%  
 
The obtained vesicle solution was filtered to remove free drug and then lyophilized to obtain dry 
clofazimine-loaded PVP-b-PVAc samples. The samples were dissolved in methanol to determine 
the drug loading content and encapsulation efficiency of the vesicles. The clofazimine content 
was determined by UV/Vis spectrometry. The concentration of the clofazimine was measured 
using a standard calibration curve (correlation coefficient 0.998) experimentally obtained from 
clofazimine/methanol solutions. Clofazimine has two UV absorbance peaks at 280 nm and 460 
nm. The clofazimine content was determined by measuring the absorbance at 460 nm to 
minimize the interference of the polymer with an absorbance at ~280 nm. The calibration curve 
is linear over the range of 0.5 – 75 µg.mL-1. 
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4.2.6 Stability studies of clofazimine-loaded PVP-b-PVAc 
The particle size stability of drug-loaded vesicles was studied in PBS and in PBS/serum under 
physiological conditions (pH 7.4, 37 °C). The clofazimine-loaded PVP-b-PVAc solution 
(prepared as described in Section 4.2.2), was diluted in phosphate buffer solution (1:9 (v/v) 
vesicle solution/PBS) at pH 7.4 (concentration of PVP-b-PVAc 0.5 mg/mL). For systems 
mimicking biological fluids, the stability of the vesicles was assessed in PBS containing 20 % 
(v/v) serum. Drug-loaded PVP-b-PVAc as prepared in Section 4.2.2 was diluted in buffer 
solutions containing FCS. The particle sizes of the vesicles were measured as a function of time 
at 37 °C by DLS.  
Clofazimine-loaded vesicles were incubated at physiological conditions (pH 7.4, 37 °C) and the 
concentration of the drug was monitored over time. 100 µL of a 20 % (w/w) clofazimine-loaded 
vesicle solution was added to 900 µL of PBS buffer at pH 7.4 and incubated at 37 °C. 20 µL 
aliquots were withdrawn at specific time intervals and the drug concentration analyzed by 
UV/Vis spectroscopy.  
 
4.3. Results and discussion 
4.3.1 Preparation and characterization of clofazimine-loaded PVP-b-PVAc block copolymers 
Clofazimine is a poorly water-soluble drug (water solubility 0.225 mg/L).20 This is illustrated in 
Figure 4.3 (A) which clearly shows the flaky, undissolved drug particles in water. To overcome 
the solubility issue, the drug was physically entrapped into PVP-b-PVAc via the dialysis method. 
PVP-b-PVAc and clofazimine were dissolved in DMSO and dialyzed against distilled deionized 
water (DMSO was chosen as solvent due to the solubility of clofazimine in this solvent). The 
gradual replacement of DMSO by water triggered the micellization of the copolymer and the 
incorporation of drug in the hydrophobic bilayer membrane and resulted in an orange, 
homogeneous dispersion as seen in Figure 4.3 (B). Clofazimine was successfully loaded into 
PVP-b-PVAc block copolymers and no drug precipitation was observed during the encapsulation 
procedure. Drug-loaded PVP-b-PVAc could either be stored in solution or in freeze-dried form. 
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The encapsulation of clofazimine into the hydrophobic PVAc bilayer membrane was confirmed 
by 1H NMR. Figure 4.4 shows the 1H NMR spectra of clofazimine-loaded PVP90-b-PVAc210 
block copolymers in different environments. Figure 4.4 (a) represents clofazimine-loaded PVP90-
b-PVAc210 block copolymer aggregates in DMSO-d6. Figure 4.4 (b) represents the 1H NMR 
spectra of clofazimine-loaded PVP90-b-PVAc210- in deuterium oxide (D2O). For clofazimine-
loaded PVP90-b-PVAc210 in DMSO-d6 (Figure 4.4 (a)) vesicle formation is not expected and all 
peaks of the hydrophilic (PVP) and hydrophobic (PVAc) segments were detected. Proton peaks 
of clofazimine were also detected (6 – 7.8 ppm as indicated with a circle on the 1H NMR 
spectrum). The formation of clofazimine-loaded PVP90-b-PVAc210 vesicles was confirmed by 1H 
NMR spectroscopy in D2O (Figure 4.4 (b). The predominant peak is that of the PVP (3 – 4 ppm) 
- the corona of the vesicle-like structure - while the peaks of PVAc are suppressed. This is due to 
the limited mobility of the PVAc-chains in the hydrophobic bilayer membrane of the vesicle. 
The intensity of the PVAc peak is reduced compared to that in Figure 4.4 (a) where the vesicles 
are not expected to be present. No peaks of clofazimine are present. This is due to the drug being 
incorporated within the vesicle bilayer membrane which restricts the mobility of the drug 
molecules resulting in suppressed proton resonances. 1H NMR indicated that amphiphilic block 
copolymer self-assembled into vesicular structures in water, comprised of a hydrophobic 
membrane (PVAc) and a hydrophilic outer shell (PVP) and that clofazimine is contained in the 
hydrophobic bilayer membrane of the amphiphilic block copolymer. 
 
 
A B 
 
 
 
Figure 4.3: A) Clofazimine insoluble in aqueous media B) Clofazimine physically encapsulated in 
PVP-b-PVAc in aqueous media  
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4.3.2 Size distribution and morphology of clofazimine-loaded PVP-b-PVAc block copolymers 
The particle size and the size distribution of drug-loaded vesicles were measured by DLS. The 
average particle size of the drug-loaded PVP-b-PVAc was 180 – 210 nm for the samples in water 
(Table 4.1).  
 
 
 
 
 
 
 
 
Reasonably narrow size distributions and monomodal pattern (PDI < 0.1) for the different block 
copolymers were obtained as presented in Figure 4.5. After loading of clofazimine, the particle 
size did not increase considerably for the different block copolymers of varying PVAc block 
length. Furthermore, the size distribution of the drug-loaded PVP-b-PVAc block copolymers was  
a 
b 
Table 4.1: Particle sizes of unloaded and drug-loaded PVP-b-PVAc (20 % (w/w) 
clofazimine/PVP-b-PVAc) measured by DLS analysis 
Polymer 
sample 
Unloaded PVP-b-PVAc 
Zave (nm) 
 
PDI Loaded PVP-b-PVAc 
Zave (nm) 
PDI 
PVP90-b-PVAc210 180 ± 3.1 0.09 190 ± 2.2 0.09 
PVP90-b-PVAc256 
PVP90-b-PVAc290 
205 ± 2.1 
200 ± 2.5 
0.06 
0.09 
200 ± 3.2 
210 ± 2.5 
 
0.09 
0.09 
 
Figure 4.4: 1H NMR spectra of a) clofazimine-loaded PVP90-b-PVAc210 in DMSO-d6 b) clofazimine-
loaded PVP90-b-PVAc210 in D2O 
 
8 7 6 5 4 3 2 1 0
ppm
a 
b 
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approximately the same as that before drug loading. Since the optimal size of a drug carrier for 
efficient delivery of an antitumor agent to a tumor is around 100 – 200 nm, the particle sizes for 
the drug-loaded PVP-b-PVAc obtained are acceptable and meet the requirements for passive 
targeting via the EPR effect.9  
 
 
 
 
 
 
 
 
 
 
 
 
In the literature, the possibility that block copolymer vesicles can transform into micelles with 
increasing amount of solubilized hydrophobic molecules has been theoretically predicted.21 In a 
study conducted by Li et al.22, the effect of the amount of hydrophobic drug loaded into the 
vesicles on the particle size was investigated. It was observed that with increasing amount of 
hydrophobic drug the particle size of the vesicles decreased. They hypothesised that a 
transformation from vesicles to micelles had occurred. It is likely that increasing amounts of 
drug results in unfavourable stretching of the hydrophobic chains which eventually results into 
micellization of the vesicles. 
 
In order to determine whether the drug content has an effect on the particle size of the PVP-b-
PVAc carrier, different drug feed ratios were investigated. Figure 4.6 shows the relationship 
between different drug feed ratios on the particle size of the PVP-b-PVAc carrier. All samples 
were prepared using the same procedure (Section 4.2.2). It was observed that the PVP-b-PVAc 
carrier sizes for the different drug formulations (5 – 20 (w/w) % drug/polymer) were in the range 
Figure 4.5: Size distribution of clofazimine-loaded PVP-b-PVAc of varying PVAc block length 
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of 190 – 210 nm. No significant change was observed. Therefore the increase in the drug content 
had no major effect on the particle size of the carrier. In the case of 30 %, drug precipitation was 
seen in the dialysis tubing and therefore samples were not analyzed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The morphology of the drug-loaded PVP-b-PVAc vesicles was visualized by TEM. As depicted 
in Figure 4.7, the average diameters of the drug-loaded PVP-b-PVAc vesicles were 150 – 200 
nm. The characteristic dark outer layer (representing the membrane bilayer or vesicle wall) and 
lighter inner core (representing the hydrated core) are clearly evident. TEM results are in fairly 
good agreement with those determined by DLS. The presence of slightly smaller particles is as a 
result of shrinkage of the particles which is consistent with similar reports studying polymer 
vesicles via TEM in the dried state.23  
 
 
 
 
 
 
Figure 4.6: The effect of different drug feed ratios (% (w/w) clofazimine/polymer) on the particle 
size of clofazimine-loaded PVP-b-PVAc of varying PVAc block length. Error bars represent the 
standard deviation (n = 3) 
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4.3.3 Drug loading capacity and encapsulation efficiency 
For any drug formulation, the drug loading capacity and efficiency are important parameters. As 
outlined in Chapter 2, the loading capacity and the encapsulation efficiency of a polymer drug 
carrier is influenced by several factors. The nature of the hydrophobic core (of micelles) or 
bilayer membrane (of vesicles), the block length of the hydrophobic core or bilayer membrane, 
the size or thickness of the core or the bilayer membrane and the degree of hydrophobicity of the 
drug are all important factors to be considered.24,25 
 
In order to find an optimal drug to polymer ratio for the PVP-b-PVAc drug carrier, a series of 
clofazimine-loaded PVP-b-PVAc with different weight ratios of clofazimine to polymer (5 %, 10 
%, 15 %, 20 % and 30 %) were prepared. The effect of the hydrophobic block length and the 
drug/polymer weight ratio on the drug loading capacity and encapsulation efficiency were 
investigated. 
 
Figure 4.8 represents the drug loading capacity and the encapsulation efficiency of clofazimine-
loaded PVP-b-PVAc of different drug feed ratios (using a constant amount of polymer). 
 
 
 
 
Figure 4.7: TEM image of clofazimine-loaded PVP90-b-PVAc290 showing the vesicular structure 
 
200 nm 
Stellenbosch University http://scholar.sun.ac.za
Chapter 4 Poly(vinylpyrrolidone)-b-poly(vinyl acetate): A potential drug carrier 
 
 83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clofazimine-loaded PVP-b-PVAc of longer hydrophobic PVAc block length (PVP90-b-PVAc290 
and PVP90-b-PVAc256) resulted in a higher drug loading capacity and encapsulation efficiency 
(having the same amount of drug) compared to PVP90-b-PVAc210 of shorter PVAc block length. 
The results follow the general trend: the loading capacity and the encapsulation efficiency of the 
polymer carrier increase with increasing hydrophobic chain length. The loading capacity of 
polymer vesicles is dependent on the molecular weight of the hydrophobic block, since 
copolymers with larger hydrophobic molecular weight can form thicker hydrophobic bilayer 
membranes. The thicker membrane can therefore accommodate more hydrophobic drug.22 It is 
also possible that the longer the hydrophobic PVAc block, the stronger the hydrophobic 
interaction between the drug and the hydrophobic bilayer membrane resulting in higher drug 
loading capacities and higher encapsulation efficiencies.  
 
The effect of the feed weight ratio on the drug loading capacity and encapsulation efficiency was 
also studied. The drug loading capacity and encapsulation efficiency increased with increasing 
initial drug feed (constant amount of polymer). As the feed amount of clofazimine increased 
from 5 – 20 %, the drug loading capacity increased from 2.7 wt % to 20 wt %, for PVP90-b-
PVAc290 and 1.4 wt % to 20 wt % for PVP90-b-PVAc256. In the case of the more hydrophilic 
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Figure 4.8: Drug loading capacity and encapsulation efficiency of clofazimine-loaded PVP-b-PVAc 
of different hydrophobic PVAc block length. Feed ratios were 5, 10, 20, or 30 weight percentage (% 
w/w) of clofazimine relative to PVP-b-PVAc. Error bars represent the standard deviation (n = 3) 
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block copolymer, clofazimine-loaded PVP90-b-PVAc210, the drug loading capacity increased 
from 5 wt % to 42 wt %. The encapsulation efficiency also increased with increasing drug feed 
amount. The encapsulation efficiency increased from 20 wt % to 60 wt % for clofazimine-loaded 
PVP90-b-PVAc290, from 13 wt % to 40 wt % for clofazimine-loaded PVP90-b-PVAc210, and 14 wt 
% to 60 wt % for clofazimine-loaded PVP90-b-PVAc256. A decrease in the encapsulation 
efficiencies for clofazimine-PVP90-b-PVAc290 and PVP90-PVAc256 was seen when a 30 % (w/w) 
drug/polymer ratio was used. This corresponded to drug precipitation that was observed in the 
dialysis tubing during the loading process, which indicated that the vesicles had reached their 
maximum loading capacity. Therefore the maximum drug/polymer feed ratio for clofazimine is 
20 %, above this value clofazimine overloading of the system occurs. Exceeding the 
solubilization capacity of the vesicles, results in release in the aqueous phase, followed by 
crystallization or precipitation of the drug as reported previously in the literature.22,26 
Interestingly, for the more hydrophilic block copolymer, the drug loading capacity reached a 
maximum loading capacity of 40 wt % with an encapsulation efficiency of 70 wt % when a 30 % 
(w/w) drug/polymer ratio was used. No drug precipitation was observed during dialysis, 
however, the sample was unable to maintain its stability upon storage. The colloidal stability of 
the drug-loaded carrier often becomes lower as the drug loading increases due to the enhanced 
hydrophobicity of the carrier after loading with hydrophobic drug.27 
 
The drug loading capacity and encapsulation efficiency is also dependent on the miscibility 
between the polymers and the hydrophobic drugs.28 In a study conducted by Letchfold et al.28, 
the solubilization of five model hydrophobic drugs by methoxy poly(ethylene glycol)-b-
poly(caprolactone) diblock copolymers (MePEG-b-PCL) was investigated. Indomethacin, 
showed the best solubility in the MePEG-b-PCL micelles, having a higher loading capacity and 
encapsulation efficiency than the poorly solubilizedetoposide. Additionally, a higher PCL block 
length also resulted in better loading capacity. 
 
For comparative purposes, paclitaxel (PTX), a commonly used anti-cancer drug (water solubility 
5.5 mg/L) was selected to evaluate the loading capacity and encapsulation efficiency of the 
polymer vesicles. PVP-b-PVAc copolymers were loaded with PTX using the same procedure as 
for clofazimine-loaded samples (Section 4.2.2).  
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The loading capacity and encapsulation efficiency obtained for the PTX-loaded PVP90-b-
PVAc290 and PTX-loaded PVP90-b-PVAc210 is presented in Figure 4.9.  Similarly to clofazimine-
loaded vesicles, the longer hydrophobic PVAc block provided a higher PTX loading capacity 
and encapsulation efficiency as expected. PVP90-b-PVAc290 (10 % (w/w) PTX/polymer) showed 
the highest drug loading levels of 15 wt % and encapsulation efficiency of 62 wt %. A further 
increase in the initial drug feed to a 20 % (w/w) PTX/polymer did not result in a greater drug 
loading level or encapsulation efficiency. Rather a decrease in encapsulation efficiency was seen 
as a result of PTX precipitation that was found inside the dialysis membrane tube. At a feed ratio 
of 20 % (w/w) PTX/polymer, no precipitation was observed for PVP90-b-PVAc210, however, the 
sample was unstable upon storage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results clearly demonstrate that the loading capacity and encapsulation efficiency of the 
PVP90-b-PVAcn vesicles is dependent on the hydrophobicity (PVAc block length) and the drug 
feed ratio. In addition, differences in the hydrophobicity of the drugs and/or compatibility with 
the PVAc domain are also important factors which could explain the differences in the loading 
capacity and encapsulation efficiency for clofazimine and PTX. However, to prove the above 
assumption solubility studies, polymer-drug compatibility parameters and partition coefficients 
will need to be determined, which at this point is beyond the scope of the study. 
Figure 4.9: Drug loading capacity and encapsulation efficiency of paclitaxel-loaded PVP-b-PVAc of 
different hydrophobic PVAc block length. Feed ratios were 5, 10, or 20, weight percentage (% w/w) of 
PTX relative to PVP-b-PVAc. Error bars present the standard deviation (n = 3) 
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Other factors such as the structural properties of the drugs can also have an impact on the loading 
capacity and efficiency. For drugs with bulky groups and high molecular weight, it is more 
difficult for high concentrations to become encapsulated in the core or the bilayer membrane due 
to steric hindrance which prevents the close stacking of the drug molecules, resulting in lower 
encapsulation efficiencies. 
 
Our final optimized formulation of clofazimine and PTX-loaded PVP-b-PVAc had a 
composition of 20 % (w/w) clofazimine/PVP-b-PVAc and 10 % PTX/PVP-b-PVAc. Due to the 
longer hydrophobic block length, PVP90-b-PVAc290 showed the highest loading capacity and 
encapsulation efficiency for both drugs. Furthermore, this polymer gave the lowest CMC (0.0012 
mg/mL) which is important for its application. PVP90-b-PVAc290 showed to be the best candidate 
for drug loading and was, therefore, further used for in vitro cytotoxicity studies (Chapter 5). 
 
4.3.4 Stability studies of clofazimine-loaded PVP-b-PVAc block copolymers 
The particle size stability of the polymer vesicles in biological fluids is important for in vitro and 
in vivo applications. The particle size stability of 20 % (w/w) clofazimine-loaded PVP90-b-
PVAc290 vesicles (polymer concentration 0.5 mg/mL) in physiological conditions (PBS, pH 7.4, 
37 ºC) was investigated using DLS. The particle sizes of clofazimine-loaded PVP90-b-PVAc290 
vesicles in PBS/FCS were also investigated.  
 
Figure 4.10 (a) shows that the average particle size of the PVP90-b-PVAc290 vesicles in PBS were 
210 – 220 nm, and stable up to 16 hours. No precipitation was observed. The same sample was 
incubated in PBS, pH 7.4 at 37 ºC. At designated time intervals, the concentration of the drug 
was monitored by UV/Vis spectroscopy. The concentration of the drug in the drug-loaded PVP-
b-PVAc sample remained constant over 24 hours. After 30 hours the concentration decreased by 
20 % due to leakage of drug from the vesicles (data not shown). For free drug incubated in PBS 
(50/50 (v/v) ethanol/PBS, pH 7.4), the formation of fluffy-like precipitate was visible after 24 
hours. This is not unexpected due to the low solubility of the drug in aqueous media. Similar 
results have also been observed for other hydrophobic cancer drugs.29  
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For clofazimine-loaded PVP90-b-PVAc290 in PBS/FCS, the average particle sizes were similar to 
the vesicles in PBS. In addition, the vesicle sizes remained stable for 15 hours in PBS/FCS. No 
drug precipitation was observed during the incubation time. Clofazimine-loaded PVP90-b-
PVAc210 also showed stability in PBS and PBS/FCS. Particle sizes of 180 – 190 nm (in PBS) and 
170 nm (in PBS/FCS) were maintained over 16 hour incubation. No drug precipitation was 
observed. This indicates that the hydrophilic PVP segment (the corona of the vesicles) was able 
to stabilize and protect the vesicles from non-specific surface adsorption of serum components. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Particle size (Zave) of clofazimine-loaded (a) PVP90-b-PVAc290 (b) PVP90-b-PVAc210 in 
(▲) PBS pH 7.4 and (●) PBS/FCS pH 7.4, as a function of time at 37 ºC 
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4.4 Conclusion 
PVP-b-PVAc block copolymers of constant hydrophilic block length and varying hydrophobic 
block length were loaded with clofazimine, via the dialysis method. The polymer could 
effectively solubilize the hydrophobic drug. 1H NMR spectroscopy confirmed the self-assembly 
of the PVP-b-PVAc block copolymers and the localization of the drug within the hydrophobic 
PVAc bilayer. The obtained drug-loaded vesicles had diameters from of 180 – 210 nm with 
narrow size distributions. The optimal clofazimine-loaded PVP-b-PVAc vesicle formulation was 
prepared using a 20 % drug/polymer feed ratio, having of a particle size of 200 nm which 
remained stable in physiological conditions. Overall, PVP-b-PVAc vesicles could be a potential 
candidate as a drug carrier for hydrophobic drugs. 
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Chapter 5 
In vitro cytotoxicity and cellular uptake of PVP-b-PVAc 
 
Abstract 
In vitro cytotoxicity studies of poly((N-vinylpyrrolidone)-b-poly(vinyl acetate)) (PVP-b-PVAc) 
and drug-loaded PVP-b-PVAc were investigated against MDA-MB-231 multi-drug-resistant 
breast epithelial cancer cells and MCF12A normal breast epithelial cells. In vitro experiments 
demonstrated that the PVP-b-PVAc drug carrier showed no cytotoxicity, confirming the 
biocompatibility of the PVP-b-PVAc drug carrier. In vitro cellular uptake of fluorescently 
labeled PVP-b-PVAc was studied using fluorescence microscopy. The PVP-b-PVAc carrier was 
taken up by the cancer cells after 6 hours and localized in both the cytoplasm and in the 
perinuclear region. From these results, we could conclude that the present PVP-b-PVAc block 
copolymer could potentially be useful as a drug carrier for hydrophobic drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Stellenbosch University http://scholar.sun.ac.za
Chapter 5 In vitro cytotoxicity and cellular uptake of PVP-b-PVAc 
 
 92 
5.1 Introduction 
One of the essential requirements of a drug carrier or a drug delivery system is that they have no 
inherent cytotoxicity.1 Prior to in vivo work, drug delivery systems are subjected to in vitro 
studies in order to determine the biocompatibility of the polymer drug carrier and the efficacy of 
the drug carrier. In vitro cytotoxicity assays and various screening assays are widely used in drug 
development to study the effect of novel compounds/drugs, drug carriers or drug delivery 
systems on healthy cells or cancer cells.2 Thus, in vitro investigation can provide preliminary 
evidence to show the advantages of a drug carrier system in drug delivery application. However, 
it must be mentioned that although in vitro studies are beneficial, they are not a true 
representation of in vivo conditions. 
 
A prerequisite for an effective polymer drug carrier, is the need for the drug to be delivered 
intracellularly to exert its therapeutic action inside the cytoplasm or into the nucleus or other 
specific organelles. In vitro cellular uptake and internalisation studies, therefore, provide 
essential information regarding the intracellular pathway and cellular distribution of the drug 
delivery carrier.  
 
In recent years, fluorescence microscopy has become an important tool for studying the in vitro 
cellular internalization and localization of polymer drug carriers.3,4 In order to confirm that the 
drug carrier has successfully delivered the drug to the target site, it is necessary to track a 
polymer drug carrier on its cellular journey. The attachment of a fluorescent label to the polymer 
backbone is a convenient way to trace the polymer.5 Commonly used fluorescent labels include 
rhodamines,6 and fluorescein dyes - sulfhydryl-reactive or amine-reactive fluorescein dyes e.g. 
fluorescein isothiocyanate (FITC)7-9, which can be conjugated to polymers having appropriate 
reactive functional groups For example, Eisenberg and coworkers showed internalization of 
micelles through bioconjugation of a rhodamine fluorescent probe onto poly(ethylene glycol)-b-
poly(caprolactone) (PEG-b-PCL) micelles.10 In a subsequent study, Savic et al.11 used a triple-
labeling approach where the nucleus, the PCL-b-PEO micelles, and the plasma membrane were 
individually labeled and selectively visualized. Fluorescence results indicated that the micelles 
were predominantly localized in the cytoplasm and distributed within several cytoplasmic 
organelles, but not in the nucleus.  
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In some cases, the drug molecules themselves consist of aromatic ring systems exhibiting 
inherent fluorescence (e.g. doxorubicin).12 Therefore, if fluorescently labeled micelles are 
combined with a drug (which exhibits fluorescence) then the fate of both the micelles and the 
drug can be detected independently. However, in order to distinguish between the drug delivery 
carrier and the drug, it is imperative that they emit fluorescence at different wavelengths (i.e. 
different colours).  
 
The versatility of the RAFT technique has previously been addressed in Chapter 2. Not only does 
it allow for the synthesis of well-defined end-functional polymers, but it also allows for 
postmodification of otherwise inert polymers.13,14 Thiol-ene chemistry is the most widely used 
and easiest accessible route to post-polymerization polymer modification on polymers 
synthesized via the RAFT technique.15,16 Thiol groups lend themselves to thiol-ene processes for 
polymer bioconjugation resulting in polymers that can be used for pharmaceutics, drug delivery 
and biomedical imaging applications.17,18  
 
Several procedures for the removal of the RAFT thiocarbonyl thio end-group, yielding thiol end-
group polymers have been thoroughly documented by Moad et al.19 There are several types of 
thiol-reactive dyes reported in the literature, including iodoacetamides, disulfides, maleimides, 
vinyl sulfones and various electron-deficient aryl halides and sulfonates. Iodoacetamides and 
maleimides are by far the most popular thiol-reactive moeities. Thiol-based polymers are 
therefore the preferred targets for these specific thiol-reactive fluorescent labels. The use of thiol-
maleimide coupling reactions has been documented in the literature.20-22 Li et al.23 described the 
first example of sequential thiol-ene reactions, involving thiol-maleimide coupling. Poly(N-
isopropylacrylamide) (PNIPAm) prepared by a trithiocarbonate RAFT agent, when reacted with 
2-ethanolamine in the presence of tributylphosphine in 1,4-dioxane, yielded the thiol-terminated 
homopolymer, PNIPAm-SH. This further reacted with bismaleimidodiethyleneglycol to yield 
maleimide end-functional PNIPAm. Similarly, Scales et al.24 synthesized fluorescently labeled 
PNIPAM polymers. End groups were cleaved with sodium borohydride (NaBH4). The thiol-
terminated polymer reacted with N-(1-pyrene) maleimide in the presence of a catalytic amount of 
ethylenediamine in DMF, which resulted in fluorescent ω-chain-end modified PNIPAm.  
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With the advancement in polymer chemistry, the development of fluorescent polymers has also 
found use in various applications in medicine, including in vitro and in vivo trafficking in drug 
delivery. This is an alternative approach to track the cellular pathway and distribution of the 
polymer drug carrier in vitro. The attachment of fluorescent labels to polymers is often restricted 
due to the limited availability of fluorescent labels with specific functional groups for 
conjugation to the polymer. In addition, the attachment of the fluorescent dyes to the polymers 
can alter the physicochemical properties of the drug carrier, which could further affect the route 
of internalisation and the intracellular distribution.11 To circumvent this, fluorescent amphiphilic 
polymers have particularly gained interest. 14,25 For example, Perrier and coworkers25 
synthesized a fluorescent, thermosensitive, amphiphilic poly(N-isopropyl-acrylamide-co-N-
vinylcarbazole) conjugated to pH responsive poly(2-(N,N-dimethylamino))ethyl acrylate, 
(PNIPPAm-co-PNVC)-b-PDMAEA. These polymers could be useful to gain insight and 
understand the in vivo fate of the drug delivery vehicle. In addition to fluorescent polymers, the 
development of fluorogenic polymers (polymers bearing a fluorogenic label, whose fluorescence 
is revealed only upon cellular uptake) for cellular internalization and trafficking studies have also 
been investigated.26  
 
In the present study, we evaluated the toxicity of the PVP-b-PVAc drug carrier. Furthermore, we 
investigated the cytotoxicity of drug-loaded PVP-b-PVAc to evaluate its potential as a drug 
delivery vehicle. The attachment of a fluorescent label to the PVP-b-PVAc carrier allowed for in 
vitro cellular uptake studies using fluorescence microscopy. Clofazimine has no inherent 
fluorescence, therefore, we considered perylene red (Exalite 613), a hydrophobic fluorescent 
probe to mimic the hydrophobic drug, clofazimine. Perylene red was physically entrapped into 
the fluorescently labeled PVP-b-PVAc using the same method as for the hydrophobic drug, 
clofazimine. The cellular uptake of the resulting fluorescently labeled perylene red-loaded PVP-
b-PVAc vesicles was explored in vitro and compared with free perylene red. 
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5.2 Materials and Methods 
5.2.1 Materials 
n-butyl amine, dichloromethane (DCM, 99 %), diethyl ether, dimethyl formamide (DMF, 98 %), 
dimethyl sulfoxide (DMSO, 99 %), Dulbecco’s Modified Eagle’s Medium (DMEM, sterile), 
tris(2-carboxyethyl)phosphine (TCEP.HCl) were purchased from Sigma Aldrich. Fluorescein 
maleimide was obtained from Sigma-Aldrich. Perylene red laser dye (Exalite 613) was obtained 
from Exciton (USA). Multi-drug-resistant (MDR) MDA-MB-231 and MCF12A cell lines were 
obtained from the Department of Physiology, University of Stellenbosch. Amphiphilic block 
copolymer, PVP90-b-PVAc290 was used in all cytotoxicity experiments. 
 
5.2.2 Cell culture and culture conditions 
MCF12A normal breast epithelial cells and MDR MDA-MB-231 breast epithelial cancer cells 
were seeded in 96-well plates with 5x104 cells/well and maintained in DMEM supplemented 
with 1 % penicillin/streptomycin (PS), 10 % fetal calf serum and 1 % L-glutamine at 37 °C in a 5 
% CO2 humidified atmosphere.

5.2.3 In vitro cytotoxicity assay 
The MTT assay is a routine, quantitative assay used to assess the response of different cell lines 
to drugs.2 This quantitative calorimetric assay is based on a yellow water-soluble tetrazolium 
salt, (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), which is reduced when 
in contact with viable cells. The reduction reaction is facilitated by the mitochondrial reductase 
enzymes, thus the conversion is directly related to the number of viable cells. In the MTT assay, 
the yellow MTT is converted to purple, insoluble formazan crystals which are solubilised by 
organic solvents (e.g. DMSO) and the resulting samples are measured by a spectrometer. The 
absorbance is proportional to the concentration of the formazan solution which is proportional to 
the number of live cells.27  
 
To determine the cytotoxicity of clofazimine and clofazimine-loaded PVP-b-PVAc, in vitro 
MTT assays were conducted on a MDA-MB-231 breast cancer epithelial cell line and a 
MCF12A healthy breast epithelial cell line. Cells were seeded in 96-well plates and cultured  
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overnight at 37 °C at a 5 % CO2 humidified atmosphere. All glassware was autoclaved (steam 
sterilized at 121 °C for 20 minutes) prior to use. The clofazimine-loaded PVP-b-PVAc was 
sterilized by filtration using 0.22 µm Millipore-Millex syringe filters. Clofazimine was dissolved 
in DMSO (0.1 %) and diluted in DMEM. Serial dilutions were made from the stock solution to 
yield final concentrations of 0.6 – 10 µg/mL of free drug. For clofazimine-loaded PVP-b-PVAc, 
the clofazimine concentration for each formulation was prepared by serial dilutions in the cell 
culture medium, to obtain final concentrations of 0.6 – 10 µg/mL. The cells were then incubated 
in DMEM containing free clofazimine and clofazimine-loaded PVP-b-PVAc for 24 hours. 
After treatment of the cells, 20 µL of MTT assay was added. The plates were incubated for a 
further 4 hours after which the medium was aspirated and the precipitated formazan was 
extracted with 200 mL of DMSO. The absorbance was measured at 570 nm using a microplate 
reader. Experiments were done in triplicate. The relative cell viability of the unloaded and drug-
loaded polymer was compared to the control cell culture in complete DMEM. 
Cell viability was calculated by the following equation 
Cell viability (%) =   	

  
 x 100 % 
where Intsample is the fluorescence intensity the sample in the cells and Intcontrol is the fluorescence 
intensity of the cells incubated in culture medium (positive control). The IC50 values of the drug 
and drug-loaded PVP-b-PVAc was calculated from the cell viability data. The concentration of 
drug required for 50 % inhibition of cell viability was determined from the dose-response curves 
(logarithmic concentration of drug or drug-loaded PVP-b-PVAc) versus % viability). 
 
5.2.4 Synthesis of fluorescently labeled PVP-b-PVAc  
Aminolysis of PVP-b-PVAc 
PVP-b-PVAc (1.2 g, 0.2 mmol) was dissolved in DCM (10 mL). After complete dissolution of 
the polymer, n-butylamine (0.073 g, 1.0 mmol, 5-fold molar excess) was added to the reaction 
mixture. The reaction was carried out for 2 hours at room temperature. The polymer was 
recovered and purified by precipitation from diethyl ether. 
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Conjugation of fluorescein maleimide to PVP-b-PVAc-SH 
PVP-b-PVAc-SH was dissolved in dry DMF (3 mL) and flushed under argon for 10 minutes. A 
solution of TCEP.HCl in DMF was added (150:1 mole ratio of TCEP to polymer). The reaction  
mixture was stirred for 2 hours at room temperature under argon flow. 100 µL of fluorescein 
maleimide (10 mM in DMF) was added to the reaction mixture after 2 hours. The reaction 
mixture was then stirred at room temperature in the dark for 24 hours. The resulting reaction 
mixture was dialyzed against water (MWCO 3.5 KDa) for 7 days at 4 °C and protected from 
light, to remove residual or unreacted fluorescein maleimide. The water was changed three times 
per day. The purified polymer was recovered by freeze-drying, stored at 4 °C and protected from 
light. 
 
5.2.5 Preparation of perylene red-loaded PVP-b-PVAc 
Perylene red-loaded PVP-b-PVAc was prepared using the same method reported previously for 
clofazimine-loaded PVP-b-PVAc. Briefly, 10 mg of fluorescently labeled PVP-b-PVAc was 
dissolved in DMSO (1 mL) and perylene red (0.5 mg). The solution was stirred for 10 minutes 
and then dialyzed against distilled deionized water for 24 hours. The water was changed every 6 
hours. The micelle solution was filtered through a microsyringe filter (0.22 µm) to remove 
aggregates and free (precipitated) dye. Dynamic light scattering (DLS) was used to determine the 
particle size (ZAve) and the particle size distribution (PSD) of the perylene red-loaded PVP-b-
PVAc. 
 
5.2.6 Cellular uptake 
15 000 cells were seeded into 8-well chambered coverglasses (NuncTM) and utilized for 
fluorescence microscopy upon reaching 80 % confluency. Nuclei were stained by using Hoechst 
33342 in a final concentration of 50 µg/mL.  
Perylene red-loaded PVP-b-PVAc (polymer concentration 5 mg/mL) was added to the cells and 
images were acquired immediately thereafter. Samples were observed on an Olympus Cell® 
system attached to an IX-81 inverted fluorescence microscope equipped with a F-view-II cooled 
CCD camera (Soft Imaging Systems). Using a Xenon-Arc burner (Olympus Biosystems GMBH) 
as light source, images were excited with the 360 nm, 472 nm or 572 nm excitation filter. 
Emission was collected using a UBG triple-  
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bandpass emission filter cube. For the z-stack image frame acquisition, a step width of 0.5 µM, 
an Olympus Plan Apo N 100x/1.4 Oil objective and the Cell® imaging software have been used.  
 
Images were processed and background-subtracted using the Cell® software. The time lapse 
images were recorded with a cycle time of 10 s for a duration of 3 minutes. Images were 
processed and background-subtracted, volume rendered and projected by using the Cell® 
software. 
 
5.3 Results and discussion 
5.3.1 In vitro cytotoxicity studies 
Many chemotherapeutic agents are limited in clinical application. This is not only ascribed to the 
poor delivery of the therapeutic drugs to the targeted sites, but also its toxicity and undesirable 
side effects on normal tissue or cells. As discussed previously, the purpose for polymer drug 
carriers is to enhance the delivery and uptake of the drug to the target sites, and to reduce the 
toxicity and side effects of the drug to normal cells. In order to achieve this effect, it is essential 
that the drug carrier system itself is non-toxic to human cells.28  
 
Prior to cell culture studies on MDA-MB-231 breast cancer epithelial cells, cytotoxicity studies 
of PVP-b-PVAc were performed on MCF12A healthy breast epithelial cells. Figure 5.1 
represents the cell viability results of various concentrations of PVP-b-PVAc on MCF12A cells. 
PVP-b-PVAc block copolymers showed no cytotoxicity (cell viability greater than 80 %) for 
concentrations 10 – 1000 µg/mL. Clofazimine-loaded PVP-b-PVAc and free drug (clofazimine) 
of different concentrations are shown to be nontoxic to normal cells (Figure 5.1 (b)). These 
results enhance the appeal of using PVP-b-PVAc block copolymers as drug carriers for 
hydrophobic drugs. 
 
 
Stellenbosch University http://scholar.sun.ac.za
Chapter 5 In vitro cytotoxicity and cellular uptake of PVP-b-PVAc 
 
 99 
 
 
 
 
 
 
 
 
 
 
In order to discriminate between drug and polymer toxicity, the cytotoxicity of “unloaded” PVP-
b-PVAc was evaluated on a MDA-MB-231 drug-resistant breast cancer cells prior to free drug 
and clofazimine-loaded PVP-b-PVAc. The cells were exposed to different concentrations of 
unloaded PVP-b-PVAc for 24 hours (Figure 5.2). The cell viability was above 90 % for polymer 
concentrations 1 – 50 µg/mL for cells treated with various concentrations of PVP-b-PVAc for 24 
hours, indicating that that polymer is non-toxic to the cells. 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Cell viability (MTT) assay of PVP-b-PVAc against MDR MDA-MB-231 breast cancer cell 
line (Mean ±SD n=3) after 24 hours 
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Figure 5.1: Cell viability (MTT) assays of (a) PVP-b-PVAc (b) clofazimine-loaded PVP-b-PVAc against 
MCF12A breast cell line (Mean ±SD n=3) after 24 hours 
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The cytotoxicity of free drug and clofazimine-loaded PVP-b-PVAc of various drug 
concentrations (1.25 – 20 µg/mL) are shown in Figure 5.3. It was found that increasing the 
clofazimine concentration decreased the viability of the cells. At low concentration of 
clofazimine, the cytotoxicity of free drug and drug-loaded PVP-b-PVAc is not obvious. 
However, at higher concentrations of clofazimine, a difference was observed. Cells incubated for 
24 hours with different clofazimine-loaded PVP-b-PVAc formulations showed higher 
cytotoxicity compared to free clofazimine. It must be pointed out that at these drug 
concentrations, the polymer is above the CMC therefore the drug is present inside the vesicles 
rather than in free form. In addition, PVP-b-PVAc showed no obvious cytotoxicity (over 90 % 
viability, Figure 5.2), which confirms that the enhanced cytotoxicity was not due to the presence 
of the PVP-b-PVAc carrier. The IC50 value for the cytotoxicity experiment is the concentration 
of drug required for 50 % inhibition of cell viability. If the PVP-b-PVAc carrier has a negligible 
cytotoxic effect on cells, then any change in the IC50 value when treated with PVP-b-
PVAc/clofazimine formulations, is as a result of increased uptake of the drug or due to an 
enhanced therapeutic effect. The IC50 value of drug-loaded PVP-b-PVAc (9 µg/mL) is much 
lower if compared to the free drug (30 µg/mL) after 24 hours incubation. It has been reported 
that polymer drug carriers often reduce the IC50 through improved drug solubility, more efficient 
uptake and improved drug trafficking within the cell.29,30 The lower IC50 confirms the synergistic 
action of the clofazimine-loaded PVP-b-PVAc formulation in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Cell viability (MTT) assays of free drug and clofazimine-loaded PVP-b-PVAc against 
MDR MDA-MB-231 breast cancer cell line (Mean ±SD n=3 ) after 24 hours 
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PTX is a widely used anticancer drug in the clinic and exhibits strong cytotoxic activity against 
various cancer types, especially breast and ovarian cancer.31 The cytotoxicity of free paclitaxel 
and paclitaxel-loaded PVP-b-PVAc formulations were evaluated using MDA-MB-231 cells, and 
compared to clofazimine. The potency of PTX was clearly demonstrated by the low 
concentration of the IC50 value of pure paclitaxel compared to pure clofazimine having the same 
concentration in MDA-MB-231 cells. Figure 5.4 shows that PTX-loaded PVP-b-PVAc 
demonstrated the same cytotoxicity (40 – 45 %) as free PTX when incubated at low 
concentrations in MDA-MB-231 cells for 24 hours. At higher PTX concentrations, the 
cytotoxicity was higher in PTX-loaded PVP-b-PVAc than free PTX. The calculated IC50 value of 
PTX-loaded PVP-b-PVAc is 0.42 µg/mL, which is lower than that of the free drug, which has an 
IC50 of 1.58 µg/mL. 
 
When the cells were incubated for 24 hours with several PTX-loaded PVP-b-PVAc formulations, 
the same trend (in which drug-loaded PVP-b-PVAc showed higher cytotoxicity than free drug) 
was observed as for clofazimine-loaded PVP-b-PVAc formulations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At this stage, the reason for the observed cytotoxicity is not exactly known but could possibly be 
explained by the mechanism of cell entry (endocytosis for polymer micelles vs. drug permeation 
for free drug).32 It is speculated that the PVP-b-PVAc drug carrier could facilitate the 
Figure 5.4: Cell viability (MTT) assays of free drug and PTX-loaded PVP-b-PVAc against MDR 
MDA-MB-231 breast cancer cell line (Mean ±SD n=3 ) after 24 hours 
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intracellular uptake of the drug, resulting in a higher concentration of drug in the cytoplasm 
which further improves the drug efficacy. Polymeric self-assemblies have previously been shown 
to enhance the in vitro cellular uptake of anticancer drugs.33 For example, Danhier and 
coworkers33 loaded poly(ethylene glycol)-b-poly(ɛ-caprolactone-co-trimethylenecarbonate) with 
PTX, which was exposed to cervix epithelial carcinoma cells for 24 hours. Results indicated that 
PTX-loaded formulations showed lower IC50 values than free PTX, which suggests that the 
polymer carrier enhanced the cellular uptake of the PTX. Similarly, Burt et al.34 loaded PTX into 
the hydrophobic bilayer of poly(butadiene)-poly(ethylene oxide) (PB-PEO) polymer vesicles. 
PTX-loaded PB-PEO vesicles also showed higher cytotoxicity compared to free PTX against 
human breast cells. In addition, the vesicles showed an increase in storage stability, beyond the 3 
hour half-life of PDLLA-PEG micelles. 
 
Polymer drug carriers have also been reported to overcome drug resistance in multidrug-resistant 
cancer cells which are overexpressed with efflux transporters and numerous other multidrug-
resistant associated proteins in the plasma membranes.35 The efflux pumps play an important role 
in protecting tissues and organs from toxic molecules.36 Among several mechanisms of drug 
resistance, P-glycoprotein (P-gp) is the best known and most extensively investigated. P-gp, a 
membrane associated glycoprotein preferentially effluxes hydrophobic compounds from the 
inside of the cell back to the extracellular space. In tumor cells, the P-gp efflux pump is believed 
to transport more than 50 % of anti-cancer drugs out of the cell membrane and contributes to the 
multidrug resistance phenomenon (MDR). Of course, other efflux transporters also contribute to 
this phenomenon and should not be ruled out. 
 
The effectiveness of a drug is dependent on its intracellular concentration. Free drug diffuses 
through the cell membrane and slowly gets transported out of the cell by efflux transporters (for 
more precise details on drug binding, drug efflux and the P-gp action, the reader is referred to the 
references)37,38. This results in a low concentration of drug in the cytoplasm, below the cell-
killing threshold which results in limited efficacy. In this way, efflux systems confer resistance to 
drugs because they reduce the intracellular concentration of the drug. On the other hand, drug 
encapsulated in a polymer carrier (being enclosed in an endosome when entering the cell) is not 
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recognized by the efflux pumps. This results in higher intracellular drug concentrations, thereby 
improving the efficacy of the drug. However, the mechanism of the effect of polymer carriers on 
the P-gp drug efflux system still remains unclear. Further research is needed to elucidate the 
exact mechanisms of the effect of drug carriers on the P-gp efflux system. 
 
5.3.2 Cellular uptake studies of fluorescently labeled PVP-b-PVAc 
PVP-b-PVAc-fluorescein maleimide was synthesised via a thiol-maleimide reaction as shown in 
Figure 5.5. An important feature specific to RAFT polymerization is the preparation of polymers 
bearing terminal thiocarbonyl thio groups, which can easily be aminolysed with primary or 
secondary amines,39 producing terminal thiol groups. A general aminolysis procedure was 
applied to the xanthate end-functional PVP-b-PVAc block copolymer to reduce the omega-
terminal thiocarbonyl thio chain-ends yielding thiol-terminal PVP-b-PVAc. The oxidative 
coupling of the thiol-functionality (resulting in disulfide formation) was minimized by 
conducting the conjugation reaction under an inert atmosphere in the presence of a reducing 
agent, tris(2-carboxyethyl)phosphine (TCEP.HCl). The thiol end-group remained as a ‘‘chemical 
handle’’ that was conjugated to the maleimide-functionalized dye, fluorescein maleimide.  
 
 
  
 
 
 
 
In order to determine whether the fluorescein maleimide was attached to the polymer, the 
fluorescently labeled PVP-b-PVAc polymer fraction that eluted at a specific retention time from 
size exclusion chromatography (SEC) was collected. The fluorescence spectrum of the fraction 
was recorded on a luminescence spectrometer (Perkin Elmer Model LS50B) at an excitation 
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Figure 5.5: Reaction scheme for the attachment of fluorescein maleimide, a thiol-reactive fluorescein 
dye, to PVP-b-PVAc 
fluorescein maleimide, 24 h 
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wavelength of 480 nm. The polymer fraction showed an emission at 512 nm, which confirms the 
presence of the fluorescent tag on the polymer. The efficiency of the conjugation reaction was 
however not determined and the amount of free dye was not quantified. It was assumed that most 
free dye was removed after extensive dialysis for 7 days followed by filtration. Perylene red 
(Exciton 613), a hydrophobic laser dye was encapsulated into the fluorescently labeled PVP-b-
PVAc via the dialysis method. The cellular uptake of the resulting perylene-loaded fluorescently 
labeled PVP-b-PVAc was explored in vitro and compared with free label (fluorescein maleimide 
and perylene red). 
 
The cellular uptake of fluorescently labeled PVP-b-PVAc encapsulated with perylene red was 
visualized using fluorescence microscopy. Cell nuclei were labeled with Hoechst 33342. 
Fluorescently labeled perylene red-loaded PVP-b-PVAc (Zave (DLS) 160 nm, PDI 0.09) were 
incubated with MDA-MB-231 breast epithelial cancer cells grown on glass cover slips and 
observed under fluorescence microscopy for 6 hours. At specific time intervals, images were 
taken to study the time-dependent uptake of the PVP-b-PVAc carrier.  
 
Incubation of breast epithelial cancer cells with “free” hydrophobic perylene red dye in PBS (0.1 
% DMSO) at 37 °C, as control, showed almost no or minimal fluorescence signal at t = 0 (Figure 
5.6 (A)).  After 1 hour and 6 hours of incubation, no obvious fluorescence or particle signal was 
detected in the intracellular or in the perinuclear region of the cells, strongly indicating that the 
free perylene red was not taken up by the cells. After 6 hours of incubation, some aggregation of 
the perylene dye far from the vicinity of the cells was observed (Figure 5.6 (B)). No fluorescent 
image was observed for the free dye inside the cells, which could be ascribed to the 
hydrophobicity of the dye and its limited solubility in aqueous media, resulting in no cellular 
uptake. Control experiment for cells incubated with “free” hydrophilic fluorescein maleimide in 
PBS (Figure 5.6 (C)) resulted in instantaneous uptake into the cells. 
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Figure 5.7 displays the fluorescence micrographs of cells in contact with perylene red-loaded 
vesicles at t = 0, t = 3 hours and t = 6 hours incubation time. Real-time imaging over the first five 
minutes of incubation showed fluorescent nano-sized particles (which represent the vesicles) 
throughout the outside region of the cells. Figure 5.7 (A), (overlay plot), clearly shows the 
distinct, well-defined black region (representing the inside region of the cell) with no detectable 
fluorescent signal indicating that no uptake has occurred. Strongly fluorescent particles were 
detected outside the cell region. The overlay of the fluorescently labeled PVP-b-PVAc (green) 
encapsulated with perylene red, results in yellow, indicating that the vesicles were intact. At this 
stage no vesicles were taken up by the cells. The real-time imaging over the first few minutes 
showed significant motion of the vesicles outside the cells with some vesicles aligning 
themselves around the cell membrane and interacting with the cell membrane. This interaction is 
said to be the initial step of endocytosis. Figure 5.7 (B) shows a low fluorescence signal observed 
in the cytoplasm, indicating that a small fraction of vesicles were taken up by the cells after 3 
hours. Strong fluorescence was still detected outside the cell wall, indicating that most of the 
vesicles still remained outside the cell. With extended incubation time, 6 hours at 37 °C, 
enhanced fluorescence was seen with a larger fraction of vesicles accumulating in the 
intracellular region with some of the vesicles in very close proximity to the cell nucleus (Figure 
5.7(C)). 
 
 
 
 
Figure 5.6: Fluorescence micrographs of MDA-MB-231 breast cancer cells incubated with 
perylene red (control) for A) t = 0 hr B) t = 6 hr C) Fluorescein maleimide (control) 
A B C 
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Figure 5.8 represents the slice viewer plot, where each slice corresponds to an X, Y or Z-axis 
position inside the cell. By viewing the volume slices, a more complete three dimensional view 
of the cell region is seen. Figure 5.8 (A), better illustrates the absence of the vesicles in the 
cytoplasmic and the perinuclear region at incubation time t = 0 as seen in Figure 5.7 (A). In 
Figure 5.8 (B) after 6 hours of incubation, the distinct cell membrane is less defined compared to  
time t = 0, (Figure 5.8 (A)) indicating that vesicles were internalized and localized in the 
cytoplasm. 
Figure 5.7: Fluorescence micrographs of MDA-MB-231 breast cancer cells incubated with: (A) 
fluorescently labeled perylene red-loaded PVP-b-PVAc at 0 hr. (B) after 3h (C) after 6h. For each 
panel, images from left to right show the cells with nuclear staining by Hoechst 33342 and 
fluorescein-maleimide labeled PVP-b-PVAc, fluorescein-maleimide labeled PVP-b-PVAc 
encapsulated with perylene red, and the overlays of both images. Scale bars correspond to 20 µm 
A 
B 
C 
20 µm 
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Figure 5.9 represents the iso-surface projection plots of the perylene red-loaded PVP-b-PVAc at 
the different time intervals. These plots clearly show the intracellular distribution of the vesicles. 
The iso-surface projection plot, Figure 5.9 (B) compared to Figure 5.9 (A), clearly shows the 
distribution of the small fraction of vesicles which have been taken up by the cells and localized 
in the cytoplasm and not in the nucleus. The iso-surface projection plot after 6 hours (Figure 5.9 
(C)) strongly indicates a distinctly different fluorescence distribution showing that the vesicles 
are more evenly distributed inside the cell cytoplasm and in the perinuclear region. 
 
 
 
 
 
 
 
 
 
 
The results showed that the PVP-b-PVAc carrier was capable of entering the cells and carrying 
the hydrophobic dye to the cells. Furthermore, during the incubation no obvious morphological 
abnormalities of the cells or cytotoxicity of the PVP-b-PVAc carrier were observed. This 
Figure 5.8: Slice viewer plots of fluorescently labeled PVP-b-PVAc loaded with perylene red in MDA-
MB-231 breast cancer cells (A) t = 0 (B) t = 6 hr  
A B 
A B C 
Figure 5.9: Iso-surface projection plots of fluorescently labeled PVP-b-PVAc loaded with perylene red 
in MDA-MB-231 breast cancer cells (A) t = 0 (B) t = 3hr (C) t = 6 hr. 
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indicated that the PVP-b-PVAc carrier was well tolerated by the cells and is non-toxic. This 
result is in agreement with our previous in vitro cytotoxicity experiments (Section 5.2) which 
showed that the carrier is non-toxic. 
 
Although the fluorescence results provided no information regarding the release of the 
hydrophobic dye during the 6 hour incubation time, evidence that the PVP-b-PVAc carrier was 
taken up by the cells and located in both the cytoplasm and the perinuclear region was clear. The 
improved solubility and efficient cellular uptake of the dye, in the dye-loaded PVP-b-PVAc 
(which mimics the drug-loaded PVP-b-PVAc to a certain extent), could further support the 
reasoning for the enhanced cytotoxicity of the drug-loaded PVP-b-PVAc compared to free drug, 
observed in the in vitro cytotoxicity experiments. Based on the observations for the dye-loaded 
PVP-b-PVAc, similar behavior is anticipated for the drug-loaded PVP-b-PVAc. If this is the 
case, then we hypothesize that for drug-loaded PVP-b-PVAc, subsequent degradation or 
dissociation of the PVP-b-PVAc carrier (most likely as a result of interaction with proteins and 
serum components) would result in the release of the hydrophobic drug in high concentrations 
within the cytoplasmic region. This would further improve the efficacy of the drug, compared to 
free drug, which is transported into the cells via a passive diffusion mechanism.40  
 
It must be pointed out that there are numerous factors that contribute towards the cellular 
internalization of polymer carriers. Cellular internalization of polymer carriers is a time, energy, 
temperature and concentration dependent process.41 In addition, the chemical composition and 
the physicochemical properties of polymeric carrier (e.g. the ratio of hydrophilic and 
hydrophobic block lengths, charge, particle size) play an important role.42 Mahmud et al.43 
demonstrated the effect of block length and molecular weight of the poly(ethylene glycol)-b-
poly(ɛ-caprolactone) (mPEG-b-PCL) carrier. Results showed that hydrophilic PEO block length 
had a more profound effect on cellular internalization compared to PCL core forming block. The 
effect of the core-forming block on the internalization of polymer carriers by different cells has 
not been fully investigated in the literature. Furthermore, the internalization of carriers is also 
dependent on the type of cell line in which the studies are carried out.44 As a result of all the 
above mentioned factors that need to be taken into account, a comparison of the cellular uptake 
results observed for the PVP-b-PVAc carrier with those of other carrier systems previously 
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reported in the literature is rather difficult. Importantly, fluorescence data showed that the PVP-
b-PVAc carrier is capable of rapid entry into the cells, an important requirement for any drug 
delivery system. 
 
5.4 Conclusion 
Cytotoxicity assays confirmed the biocompatibility of the PVP-b-PVAc carrier. The in vitro 
MTT assays showed that PVP-b-PVAc had no toxic effect on healthy breast epithelial cells and 
breast cancer epithelial cells. On the other hand, clofazimine-loaded PVP-b-PVAc showed 
significant advantages in achieving higher cytotoxicity and smaller IC50 value over free drug 
(clofazimine and PTX). Cellular uptake of the PVP-b-PVAc carrier was clearly evidenced by 
fluorescence microscopy. PVP-b-PVAc vesicles were readily taken up by the breast epithelial 
cancer cells and localized in the cytoplasmic region. From the in vitro studies it is anticipated 
that PVP-b-PVAc is a promising drug carrier to improve the efficacy of hydrophobic drugs. 
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Chapter 6 Summary and Perspectives 
6.1 Summary 
Amphiphilic block copolymers have been used extensively in drug and gene delivery research. 
Their applications in drug delivery include drug solubilization, controlled drug release and drug 
targeting. A feature unique to amphiphilic block copolymers is their self-assembly behaviour in 
aqueous environment. This attractive feature allows for the encapsulation of highly hydrophobic 
anti-cancer drugs to increase the effective solubility of these therapeutic agents. Furthermore, it 
permits drugs to be more effectively administered, transported, and eventually delivered to the 
desired targeted site through the blood stream, which consists mostly of water. 
 
The results presented in this dissertation describe the potential application of the amphiphilic 
block copolymer, poly((vinylpyrrolidone)-b-poly(vinyl acetate)) (PVP-b-PVAc) as an effective 
drug carrier for hydrophobic anti-cancer drugs. In this chapter the results of the dissertation are 
summarized and future perspectives are given. 
 
In Chapter 1, a general introduction, the aim of the study and structure of the dissertation is 
given. The primary objective of this study was to develop a PVP-b-PVAc polymer drug carrier 
and explore its potential as a drug carrier. The physicochemical properties, formulation stability 
and anti-cancer activity of the carrier were examined. 
A general overview of amphiphilic block copolymers in drug delivery is presented in Chapter 2. 
The chapter discusses the properties of drug carriers (e.g. particle size, size distribution, drug 
loading capacity, drug release, stability) which determine their ability to deliver drugs. The 
chapter also highlights the various key factors that primarily influence these properties.  
The synthesis, characterization and self-assembly of PVP-b-PVAc is described in Chapter 3. 
The amphiphilic block copolymers were synthesized via the RAFT/MADIX technique. PVP-b-
PVAc block copolymers may be synthesized by a two-step sequential monomer addition 
polymerization procedure. The methodology consisted of growing the PVAc chain from a 
xanthate end-functional PVP. Block copolymers of constant hydrophilic PVP block length (Mn 
~10 000 g/mol) and varying hydrophobic block length were synthesized. In aqueous medium, the 
hydrophilic PVP segment forms the shell/corona region and hydrophobic PVAc segment forms 
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the bilayer membrane region where the hydrophobic molecules can be entrapped. In this 
dissertation the PVP-b-PVAc self-assembled system were formed via the dialysis method.  
The self-assembly was confirmed by 1H NMR spectroscopy in D2O. Both the morphology and 
the average size of the self-assembled PVP-b-PVAc were investigated by dynamic light 
scattering (DLS), transmission electron microscopy (TEM) and static light scattering (SLS). 
Results revealed the formation of spherical, vesicular-like particles of 180 – 200 nm in diameter. 
Considering their size, these particles are expected to be suitable for the delivery of drugs to 
tumors.1 The self-assembly behaviour of the block copolymer in aqueous solution was further 
investigated by fluorescence spectroscopy. The critical micelle concentration (CMC) of the PVP-
b-PVAc block copolymers was determined using pyrene as a fluorescent probe. Increasing the 
PVAc block length resulted in a lower CMC, which can be attributed to the increased 
hydrophobicity of the PVP-b-PVAc block copolymer. The CMC values were low (~ 0.001 
mg/mL – 0.01 mg/mL), which is important in order for the self-assembled structures to remain 
intact after dilution upon intravenous administration. Furthermore, the stability of the block 
copolymers was also assessed under physiological conditions (PBS, pH 7.4, 37 °C) and were 
stable in the absence and presence of serum.  
 
The feasibility of PVP-b-PVAc as a drug carrier for the solubilization and delivery of 
hydrophobic anti-cancer drugs was addressed in Chapter 4. To assess the potential of PVP-b-
PVAc as a drug delivery vehicle, the loading of a model drug, clofazimine, and a commonly 
used anti-cancer drug, paclitaxel (PTX), into PVP-b-PVAc was investigated. A simple loading 
method, namely the dialysis method was used to entrap the drugs in the hydrophobic PVAc 
domain. It was found that PVP-b-PVAc was able to successfully solubilize the chemotherapeutic 
agents. 1H NMR spectroscopy confirmed the formation of phase-separated structures and the 
localization of the drug within the hydrophobic domain.  
 
The method used allowed for reproducible formation of drug-loaded PVP-b-PVAc vesicles, in 
the size range of 180 – 200 nm. These particle sizes should be suitable for passive targeting via 
the enhanced permeation and retention (EPR) effect.  
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In order to find an optimal formulation for the drug-loaded PVP-b-PVAc, various factors that 
influence the loading capacity namely the length of the hydrophobic PVAc segment and the 
amount of feed drug were also investigated. Different ratios of drug and polymer were explored 
and it was found that the composition of 20 % (w/w) clofazimine: PVP90-b-PVAc290 (w/w) and 
10 % (w/w) for PTX: PVP90-b-PVAc290 were the optimum formulations. Lower ratios led to 
lower efficiency, whereas at higher ratios the PVP-b-PVAc carrier exceeded its solubilization 
capacity resulting in drug precipitation. Generally, the different PVP-b-PVAc block copolymers 
of varying PVAc block length had different loading capacities, which indicated that the 
hydrophobic block length affects the ability to load hydrophobic drug within the bilayer 
membrane. Increasing the amount of feed drug also increased the drug loading capacity. DLS 
and TEM of the drug-loaded PVP-b-PVAc showed particle sizes of 200 nm which is suitable for 
passive targeting via the enhanced permeation and retention (EPR) effect. The effect of the drug 
loading on the particle size was also investigated and found to have no significance on the 
particle size of the PVP-b-PVAc carrier. The stability of the drug-loaded PVP-b-PVAc was 
investigated in physiological conditions (PBS, pH 7.4, 37 °C) in the presence and absence of 
serum. Drug-loaded PVP-b-PVAc was stable in the presence of serum indicating that the 
hydrophilic PVP corona was able to stabilize the vesicles. 
 
Next, in vitro studies of PVP-b-PVAc were conducted and presented in Chapter 5. These studies 
are an essential first step to assess the drug carriers potential. Cytotoxicity assays confirmed the 
biocompatibility of the PVP-b-PVAc carrier. PVP-b-PVAc was shown to be non-toxic to healthy 
MCF12A breast cells and MDA-MB-231 multi-drug-resistant breast epithelial cancer cells. The 
MTT assays show that the PVP-b-PVAc carrier can deliver clofazimine and PTX and prohibit 
growth of cancer cells in vitro. In addition, the drug-loaded polymers showed increased 
cytotoxicity compared to free drug against breast cancer epithelial cells, indicating the enhanced 
therapeutic effect. To determine whether the PVP-b-PVAc carrier was taken up by the cells, 
fluorescently labeled PVP-b-PVAc was loaded with hydrophobic dye (perylene red) which 
mimicked the drug. In doing so, one is able to track whether the carrier is taken up by the cells 
and determine the fate of both the vesicles and the dye upon cellular internalization. 
Fluorescence indicated that the PVP-b-PVAc carrier was taken up by the cells within 3 hours 
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incubation and localized in the cytoplasm and perinuclear region, but not in the nucleus after 6 
hours. 
 
6.2 Perspectives 
The results presented in the thesis indicate the potential of the amphiphilic PVP-b-PVAc block 
copolymer as a carrier for hydrophobic anti-cancer drugs. However, further optimization and 
development of the system need to be considered.  
 
In terms of the PVP-b-PVAc drug carrier system developed so far in this study, the following 
aspects require further research: 
• In vitro studies 
In Chapter 5, the cellular internalization and localization and the time taken for cellular 
uptake of the PVP-b-PVAc carrier was investigated. From the results, it was anticipated 
that the cellular uptake of the carrier is via endocytic pathways, which is suggested for 
most polymer carriers. However, the specific mechanism of endocytic uptake of the drug 
carrier, the intracellular trafficking pathway the carrier follows upon cell entry and the 
subcellular distribution still remains unknown. Understanding of the cellular uptake 
routes and trafficking is essential for the development of efficient drug delivery carriers. 
These questions can be answered by staining the organelles in the cell e.g. cell membrane 
or mitochondria by using, membrane- or organelle-selective dyes.2 The answers to these 
essential questions could provide valuable information, which could further be used to 
improve the PVP-b-PVAc drug carrier system. 
 
• In vivo studies 
In Chapter 4 and 5, data on the stability of the PVP-b-PVAc carrier in physiological 
conditions as well as data on the cytotoxic effect of the PVP-b-PVAc carrier and 
clofazimine and PTX-loaded PVP-b-PVAc on MDA-MB-231 multi-drug-resistant breast 
epithelial cancer cells are presented. For many polymer drug delivery systems, promising 
in vitro stability and efficacy data on culture cells has proven to be poorly representative 
of the performance or effectiveness of the drug carriers in vivo. To date we could only 
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evaluate and demonstrate the effectiveness of PVP-b-PVAc in vitro, however, in vivo 
evaluation needs to be considered. What remains to be achieved is to test whether drug-
loaded PVP-b-PVAc can alter the pharmacokinetics of free drug in vivo.  
In addition, the in vivo biodistribution and pharmacokinetic studies need to be performed 
to confirm the therapeutic efficacy of the drug-loaded PVP-b-PVAc carrier. 
 
• Towards a more controlled drug delivery system 
The dissertation describes the first steps towards the development of a PVP-b-PVAc drug 
carrier. However, further development for a more effective drug release system should be 
considered. Firstly, an important requirement of a drug carrier is to maintain its integrity 
during circulation time upon intravenous administration. Because of the relatively high 
hydrophobic PVAc block length, the CMCs of the PVP-b-PVAc block copolymers 
developed and described in the thesis were low and the assemblies that were formed were 
correspondingly stable. This should maintain their integrity upon dilution. However, 
interaction with serum proteins can also destabilize the carrier. This results in premature 
release of the drug or alternatively accelerates the release of the drug from the carrier. 
One approach would be to covalently link the drug to the hydrophobic block via a 
hydrolytically sensitive linker (e.g. hydrazone linker). In this way, the drug remains 
stably linked to the polymer and only upon entering the acidic tumor environment or the 
acidic organelles is the drug released. To further improve the efficacy of the carrier, 
selective targeting groups can also be attached to the carrier. Alternatively, an 
amphiphilic copolypeptide drug carrier can also be considered whereby the hydrophobic 
drug is covalently linked to the carrier. Peptides exhibit high biological specificity which 
could further enhance the drug targeting property of the carrier. 
 
• Combination therapy - Multiple drug delivery 
Over the past years, research has focused on single drug administration, while not much 
attention has been placed on combination administration. Recent cancer research is based 
on combination therapy – the use of synergistic anticancer drug “cocktails” whereby two 
different drugs are delivered to tumors simultaneously.  
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Synergistic drug combinations produce an even greater response rate than is possible with 
each drug used alone at its optimum dose.3 Generally, anti-cancer drugs are typically 
administered at their individual maximum tolerated doses.4 This is termed the “more-is-
better” approach. However, this approach ignores the possibility of subtle concentration 
and ratio dependent dynamic interactions capable of causing a synergistic response.5 
Recently, a more rational approach for the combination of anticancer drugs has been 
proposed – the fixed ratio drug combinations (FRDC) approach – which holds the 
promise of capturing the maximum pharmacodynamic cytotoxic specificity for cancer 
cells. 
 
Riminophenazines possess a potent anticancer multi-mechanism that is thought to be best 
utilised in combination with standard chemotherapeutics. Interestingly, these 
riminophenazines have been shown to inhibit P-glycoprotein (P-gp), the transmembrane 
efflux pump that is largely responsible for acquired resistance.6,7 Recently, FRDC 
comprising clofazimine in combination with paclitaxel has demonstrated synergistic 
antiproliferative activity in vitro against a multi-drug resistant (MDR) cell line. Recently, 
the in vitro optimal synergistic fixed drug ratio combination of clofazimine-PTX has been 
determined (Combination Index Analysis (CI) < 1).8 The work presented in this study has 
shown that PVP-b-PVAc may serve as a suitable carrier for single delivery of 
hydrophobic drugs namely clofazimine and PTX. Therefore, current work focuses on the 
encapsulation of the FRDC of clofazimine and paclitaxel into PVP-b-PVAc. Lastly, 
owing to the vesicular morphology of the self-assembled PVP-b-PVAc, its potential for 
the simultaneous delivery of a combination of hydrophobic (e.g. PTX) and hydrophilic 
drugs (e.g. doxorubicin) can also be explored. 
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